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Background:  
Major chronic diseases such as cardiovascular disease, renal dysfunction and metabolic 
syndrome are having excessive impact on African Americans with higher prevalence rates, 
mortality and morbidity. But, relatively very few studies have been conducted among 
populations of African ancestry to evaluate the disease burden and etiology. This proposed study 
was built upon seven large, multigenerational families of African descent, residing on the island 
of Tobago, to investigate the genetic impact on major chronic diseases, and to evaluate the 
association of novel biochemical markers with subclinical cardiovascular measurements.  
 
Methods: 
Lipid profiles, subclinical cardiovascular measurements and renal function biomarkers 
were measured in 402 Afro-Caribbean individuals, aged 18 to 103 years, from 7 large, multi-
generation pedigrees (average family size: 50; range: 19 to 96; 3535 relative pairs). Estimated 
GFR was calculated using the Modification of Diet in Renal Disease Study (MDRD) formula for 
standardized serum creatinine. Heritability (h2) of cardio-metabolic renal traits was estimated 
employing maximum likelihood methods using SOLAR (Sequential Oligogenic Linkage 
Analysis Routines). Multivariate regression analysis was performed to assess the association 
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between renal function biomarkers and the subclinical cardiovascular measures, incorporating 
the effects of the relatedness of family members. 
 
Results: 
We determined that, among these Afro-Caribbeans of Tobago, renal function and 
metabolic syndrome related traits are all heritable phenotypes. The additive genetic effects 
accounted for 20-30% of the residual variation of several kidney function related traits. The 
heritability of each metabolic component ranged from 21% for large waist circumference to 46% 
for HDL-cholesterol (P<0.05). Using the National Cholesterol Education Program Expert Panel 
(NCEP) and Treatment of High Blood Cholesterol in Adults (Adult Treatment panel III) (ATP 
III) definition, 18.6% (23.3% women and 11.8% men) of the participants had metabolic 
syndrome.  
As a novel renal function biomarker, Cystatin C has heritability of 0.32 ± 0.1 (P<0.0001), 
after adjusting for age, gender, hypertension, triglyceride and insulin level. Not only does 
cystatin C indicate renal function, but it was also significantly associated with ABI (P=0.02) and 
PWV (P=0.04) in this Afro-Caribbean population. Serum creatinine, microalbuminuria and 
eGFR were not found to be related to subclinical cardiovascular disease. 
 
Public Health Significance: 
This work was the first to estimate the heritability of renal function biomarkers and 
metabolic syndrome related traits among an African ancestry population living in the Caribbean. 
The significant finding of the association between serum Cystatin C level and subclinical 
cardiovascular disease suggest a promising biomarker for both renal function and cardiovascular 
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disease. If this result is confirmed, Cystatin C could be a useful prognostic tool in this high risk 
population. 
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1.0 INTRODUCTION 
1.1 DISSERTATION OVERVIEW AND OBJECTIVES 
Cardiovascular disease (CVD) is defined as the disease condition of the heart and blood 
vessels. It is the leading cause of death in United States, nearly 2600 Americans die as a result of 
CVD every day. Actually, the pathological process starts many years before the life-threatening 
events occur. Studies show strong evidence that the incidence of CVD is substantially increased 
for people with subclinical cardiovascular disease compared to those without subclinical disease 
(1). The impact of ethnicity and race on subclinical CVD has been identified. African Americans 
have significantly lower amounts of coronary artery and carotid artery calcified plaque relative to 
whites despite having increased carotid inter media-wall thickness (IMT) and blood pressure(2). 
Both pulse wave velocity (PWV) and ankle-brachial index (ABI) are well-established, non-
invasive and easily performed measurements for subclinical CVD. High PWV assesses the 
arterial stiffness, which is a significant and independent predictor of CVD. ABI is an indicator 
for peripheral arterial disease (PAD) which increases individuals’ risk for heart attack or stroke.  
Metabolic syndrome (MetSyn), previously called insulin resistance syndrome, is 
characterized as clusters of risk factors including abdominal obesity, hypertension, dysglycemia 
and dyslipidemia (characteristically, increased triglyceride level and reduced high-density 
lipoprotein (HDL)). The prevalence of MetSyn among U.S. adults is high and increasing. High 
blood pressure, excessive waist circumference, and hypertriglyceridemia accounted for much of 
the increasing prevalence rate(3). Studies have found that MetSyn is a useful predictor for 
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cardiovascular disease and diabetes (4). The Atherosclerosis Risk in Communities Study (ARIC) 
studied prospectively the link between MetSyn and CKD. They found that among participants 
with MetSyn, the risk of CKD increased by 50%; the more traits of the syndrome, the higher risk 
for developing chronic kidney disease(5).  
Chronic kidney disease (CKD) is a worldwide public health problem, with dramatically 
increased incidence and prevalence. It is a highly costly disease due to the number of patients 
who progress to kidney failure requiring dialysis or transplantation. Although, the mortality rate 
of cardiovascular disease and all-cause death are significantly higher among African Americans 
than those for Caucasians(6, 7), black individuals with serious CKD or end stage renal disease 
(ESRD) have consistently shown a survival advantage compared to white individuals(8). It has 
been hypothesized that black individuals who live long enough to reach the serious stage of renal 
disease are healthier compared to white individuals(8). Substantial evidence has shown the 
potential links between CKD and CVD. It has been reported that reduced renal function is not 
only related to multiple traditional cardiovascular risk factors such as hypertension, 
dyslipidemia, diabetes and hypertrophy, but also related to nontraditional factors such as 
inflammation and oxidative stress(9). Community based studies have identified kidney disease as 
an additional risk factor for the development of CVD(10).  
The heritability of these complex diseases has been documented. The Northern 
Manhattan Family study, recruiting over eight hundred individuals from Hispanic Caribbean 
families, has documented the heritability of MetSyn to be 24%, with significant heritability for 
lipid/glucose/obesity (44%) and hypertension (20%)(11). The heritability of ankle brachial index 
(ABI) is about 27%, which has been estimated in a Caucasian population, the Framingham 
Offspring Study (12).  However, such finding has not been replicated in various ethnicity groups, 
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especially among African American populations, which are at higher risk for cardiovascular and 
renal disorders.  
Overall, this proposed research is to add the body of knowledge for the contributing 
factors, including biochemical markers, which increase the risk for major complex diseases. 
Cystatin C is not only a novel biomarker for renal disease, but also shows its association with 
cardiovascular system. This research seeks to investigate the association between renal measures 
both the traditional biomarker – serum creatinine, and the novel one – cystatin C, and subclinical 
cardiovascular disease among an African Caribbean population.  Figure 1 is the proposed 
biological model for this project. 
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Figure 1.1 Proposed Biological Model for the Dissertation Research Proposal 
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1.1.1 Specific Aims 
The objective of this project was achieved by three research studies which were built upon 
an existing collection of Afro-Caribbean family members who participate in the Tobago Family 
Health Study.  
Specific Aim 1: to estimate the heritability of renal dysfunction in Tobago 
multigenerational families. 
Specific Aim 2: to estimate the heritability of metabolic syndrome and its components in 
Tobago multigenerational families.  
Specific Aim 3: to determine the association of renal function biomarkers with subclinical 
cardiovascular disease in Tobago multigenerational families.  
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1.2 EPIDEMIOLOGY  
1.2.1 Cardiovascular Disease (CVD) 
Cardiovascular Disease (CVD) is defined as dysfunctional conditions of the heart, 
arteries, and veins that supply oxygen to vital life-sustaining areas of the body. CVD includes 
various forms: high blood pressure, coronary heart disease, heart failure and stroke. According to 
American Heart Association (AHA) statistics, 16,000,000 people alive today have a history of 
heart attack, angina pectoris or both. CVD, primarily heart disease and stroke, is the Nation's 
leading killer for both men and women among all racial and ethnic groups(13). Almost 1 million 
Americans die of CVD each year, which adds up to 42% of all deaths. CVD costs the nation 
$274 billion each year, including health expenditures and lost productivity. The burden continues 
to grow as the population ages. Worldwide, various forms of CVD make up an estimated 16.7 
million - or 29.2% of total global deaths according to World Health Report 2003. Heart disease 
and stroke make up more than 50% of the deaths and disability, killing more than 12 million 
people each year, however, it can be prevented simply by reducing major risk factors such as 
high blood pressure, high cholesterol, obesity and smoking (WHO report). Heart disease is no 
longer only a disease condition of the developed world: about 80% of all CVD deaths worldwide 
took place in developing countries, which also accounted for 86% of the global CVD disease 
burden. It is estimated that by 2010, CVD will be the leading cause of death in developing 
countries (WHO report). 
In the U.S., the death rate of heart disease has been decreasing since the 1960’s. The 
mortality rate of the major form of CVD, coronary heart disease (CHD), declined from 1990 
(558,291 deaths, NHLBI) to 2004 (481,458 deaths, CDC), the age adjusted death rate declined 
7 
 
about one third, from 224.3 to 154 per 100,000 population with CHD. But it is still the leading 
cause of death in the U.S. The impact of ethnicity and race on heart disease is substantial. On one 
hand, the incidence and prevalence rate are the higher among black population compared to 
whites in both gender groups. The incidence rate is 540 per 100,000 and the prevalence rate is 
262.0 per 100,000 among U.S. black males, while, the incidence rate is 450 per 100,000 and the 
prevalence rate is 228.4 per 100,000 among the U.S. white males. CHD is less prevalent in 
females compared to males, the incidence and prevalence rate for black females is higher than 
white females (American Heart Association, NHLBI website). On the other hand, CHD mortality 
has declined faster in whites than in blacks, particularly for men. The underlying explanation of 
the disparities between blacks and whites in CHD prevalence and mortality rate is complicated, 
not easily untangled. It could be attributable to a net of individual risk factors, social economic 
status (SES) and the availability, acceptability and utilization of medical services. Compared to 
whites, blacks had higher a level of risk factors; for example, in previous epidemiological 
studies, blacks were found to have higher blood pressure(14) and glucose levels as well as higher 
prevalence of obesity and diabetes(15). Further, distinct racial differences are observed among 
the SES indicators. Blacks have been reported to be likely to have a lower school education, and 
decreased household income strata, and to work in the blue collar sector (16). 
The pathological process in the cardiovascular system starts many years before the life-
threatening events occur. Studies show strong evidence that the incidence of CVD is 
substantially increased for people with subclinical cardiovascular disease compared to those 
without subclinical disease (1). Racial difference is observed. African Americans have 
significantly lower amounts of coronary artery and carotid artery calcified plaque relative to 
whites despite having increased carotid intima-to-media wall thickness (IMT), measured by B-
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mode Ultrasound examination and blood pressure(2). In contrast, African Americans were found 
to show greater arterial stiffness than Caucasians; such disparities occurred early in life (17). 
Arterial stiffness is the major component of cardiovascular disease. Increases in arterial stiffness 
increase the central systolic and pulse pressure, and decrease the perfusion pressure through the 
coronary arteries, therefore increasing the risk of coronary heart disease, myocardial infarction, 
and stroke. Pulse wave velocity is a well-established technique for assessing aortic stiffness, 
arteriosclerosis (18-20) or atherosclerosis (21-24) by measuring the velocity of the pulse wave 
between the carotid and femoral peripheral artery sites. The velocity of the pulse wave along an 
artery increases with increasing stiffness of that artery.  
1.2.2 Peripheral Vascular Disease (PVD)  
Peripheral vascular disease (PVD) is a slow and progressive circulation disorder, which 
involves diseases in any of the blood vessels outside of the heart vessels - the arteries, veins, or 
lymphatic vessels. When PVD occurs in the arteries outside the heart, it is referred to as 
peripheral arterial disease (PAD). PVD is caused by atherosclerosis, which is a progress of 
building up of fatty material within the vessels. Of the peripheral arteries, legs are most often 
affected. Other arteries frequently affected by atherosclerosis include those supplying blood to 
the kidneys or arms.  
PVD is a very common condition in the U.S. It affects about 8 million Americans, about 
half are asymptomatic. PVD increases with age dramatically, affecting about 12 to 20 percent of 
the population by age 65.  Diagnosis is critical, as people with PAD have much higher risk for 
heart attack or stroke. Detection can be relatively easy and inexpensive, based either on 
subjectively supplied historical information or upon physical examination. The ankle–brachial 
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index (ABI), the ratio of the ankle to brachial systolic blood pressure, is used to assess 
individuals with peripheral arterial disease. A ratio <0.90 indicates the presence of flow-limiting 
arterial disease affecting the limb(25). The ABI serves as a marker for increased risk for systemic 
vascular disease. It is a simple and noninvasive test that can be performed in the office or clinic 
setting. Epidemiology of risk factors for PVD is similar to coronary heart disease. Compared to 
women, men are slightly more likely to have PVD. Peripheral vascular disease is more common 
in smokers, and the combination of diabetes and smoking almost always results in more severe 
disease. Higher prevalence of lower extremity PAD in black populations has been documented, 
but the higher risk cannot be fully explained by differences in traditional cardiovascular risk 
factors (26). A recent study indicated that vitamin D deficiency may explain nearly one third of 
the excess risk of PAD in U.S. black compared with white adults (27). 
1.2.3 Chronic Kidney Disease (CKD) 
Chronic kidney disease (CKD), also known as chronic renal disease, is a progressive 
loss of renal function over a period of months or years through five stages. Each stage is a 
progression through an abnormally low and deteriorating glomerular filtration rate, which is 
usually estimated indirectly by the creatinine level in blood serum(28). Chronic kidney disease is 
a worldwide public health problem, with dramatically increasing incidence and prevalence. It is a 
highly costly disease, due to the number of patients with kidney disease who progress to kidney 
failure requiring dialysis or transplantation. Worldwide prevalence of kidney failure varies based 
on the availability and access to health resources, especially kidney replacement therapy, but is 
growing in most countries.   
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CKD is becoming a public health problem in the United States. The U.S. Renal Data 
System has declaimed that the number of  persons with kidney failure requiring dialysis therapy 
or transplantation increased dramatically from 340,000 in 1999 to 398,000 in 2000, and a 
projected 651,000 patients in 2010(29). The estimated prevalence of CKD in the U.S. adult 
population was 11% (19.2 million), based on the National Health and Nutrition Examination 
Survey (NHANES) (30). For the analysis of NHANES III data, glomerular filtration rate (GFR) 
was estimated from serum creatinine concentration using a prediction equation derived from the 
Modification of Diet in Renal Disease (MDRD) Study, as demonstrated in Table 1.1 (31). An 
estimated 5.9 million individuals (3.3%) had stage 1 (persistent albuminuria with a normal GFR), 
5.3 million (3.0%) had stage 2 (persistent albuminuria, GFR of 60 to 89 mL/min/1.73m2), 7.6 
million (4.3%) had stage 3 (GFR, 30 to 59 mL/min/1.73 m2), 400,000 individuals (0.2%) had 
stage 4 (GFR, 15 to 29 mL/min/1.73 m2), and 300,000 individuals (0.2%) had stage 5, or kidney 
failure. For stage 1 and 2, kidney damage, assessed by spot albumin-to creatinine ratio > 17 mg/g 
(men) or >25 mg/g (women) based on one occasion, was 5.9% and 4.0% respectively, or 3.3% 
and 3.0% based on two measurements. The estimated population from stages 1-4 came from 
NHANES III  (1984-1994) and stage 5 came from USRDS (1998). There are not yet projections 
for future prevalence of CKD. 
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Table 1.1  Prevalence of Stage of Chronic Kidney Disease and Levels of Kidney Function in the 
U.S. 
Stages of CKD Levels of Kidney Function 
 N(1000’s)* (%) GFR 
(mL/min/1.73m2) 
N(1000’s)* (%)** 
1 10,500
a 
5,900 
5.9 a 
3.3 
≥90 114,000 64.3 
2 
7,100a 
5,300 
4.0 a 
3.0 60-89 55,300 31.2 
3 7,600 4.3 30-59 7,600 4.3 
4 400 0.2 15-29 400 0.2 
5 300 0.2 <15 (or dialysis) 300 0.2 
 
* Data for stage 1-4 from NHANESIII (1988-1994). Population was 177 million with age 
≥ 20 years. Data for stage 5 from USRDS (1998), includes approximately 230,000 patients 
treated by dialysis, and assumes 70,000 additional patients not on dialysis. Percentages total 
>100% are because NHANESIII may not have included patients on dialysis. GFR estimated 
from serum creatinine using MDRD study equation based on age, gender, race and calibration 
for serum creatinine.  
** The reason for the percentage >100% is that NHANES III may not have included 
patients on dialysis. The GFR estimation was based on MDRD equation(32), using serum 
creatinine. 
 a: For stage 1 and 2, kidney damage was assessed by spot albumin-to creatinine ratio > 17 
mg/g (men) or >25 mg/g (women) on one occasion (larger prevalence estimate) or on two 
measurements (smaller prevalence estimate).  
 
Adapted from: K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: 
Evaluation, Classification, and Stratification 
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Although, the mortality rate of cardiovascular disease and all-cause death are 
significantly higher among African Americans than those for Caucasians(6, 7), black individuals 
with serious CKD or end stage renal disease (ESRD) have consistently shown a survival 
advantage compared to white individuals(8).  It has been hypothesized that black individuals 
who live long enough to reach the serious stage of renal disease are healthier compared to white 
individuals(8). In contrast, higher mortality rates among younger black individuals could be 
attributed to factors other than biological differences, such as education, socioeconomic status 
and access-to-healthcare. 
1.2.4 Metabolic Syndrome (MetSyn) 
Metabolic syndrome (MetSyn) previously called insulin resistance syndrome or 
syndrome X, is characterized as clusters of risk factors including abdominal obesity, 
hypertension, dysglycemia and dyslipidemia (characteristically, increased triglyceride level and 
reduced high-density lipoprotein [HDL]). Metabolic syndrome and insulin resistance syndrome 
are two terms that have been used to characterize some of the abnormalities associated with 
insulin resistance and to recognize them as risk factors for future disease. (33) There are many 
published versions of the definition for MetSyn, varying combinations of above listed risk 
factors. Literature review indicates at least five published definitions (listed in Table 2), as 
proposed by the World Health Organization (WHO), National Cholesterol Education Program 
Adult Treatment Panel III (NCEP ATP III) , European Group for the Study of Insulin Resistance 
(EGIR), American Association of Clinical Endocrinologists(AACE), and, most recently, the 
International Diabetes Federation (IDF) (34-39). The ATP III definition will be used in this 
proposal due to its wide acceptance, which facilitates the comparability of our findings to other 
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studies such as NHANES III. Six components of metabolic syndrome are included: abdominal 
obesity, atherogenic dyslipidemia, raised blood pressure, insulin resistance ± glucose intolerance, 
proinflammatory state and/or prothrombotic state(34).  
Rather than a single disorder or disease, MetSyn is relatively a new term, which has been 
used to describe a cluster of disorders that together increase the risk for diabetes and heart 
disease (4).  Data from NHANES III (Third national Health and Nutrition Examination Survey) 
revealed the overall age-adjusted prevalence for MetSyn based on ATP III definition in the 
United States was about 24%, with the prevalence for each individual components being 38.6% 
for increased waist circumferences, 30.0% for hyper-triglyceridemia, 37.1% for lower HDL, 
34% for hypertension and 12.6% for dysglycemia(40).  However, variation in prevalence of 
metabolic syndrome across population is influenced by the use of different definitions, as well as 
by differences in distributions of individual metabolic traits across population. Different patterns 
of metabolic risk factor prevalence do exist across ethnic groups / populations.  
The difference in prevalence of MetSyn components by race, age and gender has been 
documented. Based on ATP III definition, Mexican Americans had the highest age-adjusted 
prevalence of the metabolic syndrome (31.9%) compared to Caucasians (23.8%) and African 
Americans (21.6%). The prevalence increased with age, from 6.7% among young adults (20-29 
years old) to 43.5% among aged 60-69 years and 42% among 70 and above decades. Among 
Caucasians, men and women have similar prevalence (24% for men vs. 23.4% for women). But, 
among African Americans, women had about 57% higher prevalence than men and among 
Mexican Americans, women had about a 26% higher prevalence than men(40). 
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Figure 1.2 Age-Adjusted Prevalence of the Metabolic Syndrome Among 8814 US Adults Aged 
at Least 20 Years, by Sex and Race or Ethnicity, NHANES III, 1988-1994  
Data are presented as: percentage (SE) (the figure was adapted from the reference (40)) 
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The prevalence of metabolic syndrome is high among U.S. adults and increasing. The 
age-adjusted prevalence for MetSyn (using ATP III definition ) was 24.1% (40) in NHANES III 
(1988-1994) and 27.0%(3) in NHANES III 1999-2000 respectively. The age-adjusted prevalence 
increased by 23.5% among women and 2.2% among men. For each individual component, high 
blood pressure, waist circumference and hypertriglyceridemia accounted for much of the 
increased prevalence rate, especially among women (3). The similar trend of increased 
prevalence rate for MetSyn was found in European countries (41, 42). The epidemic in childhood 
obesity results in a continuing increased prevalence of metabolic syndrome, and increased the 
risk for heart disease and diabetes as well (43). Thus, it is becoming a public health problem in 
the U. S. and worldwide. 
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Table 1.2 Comparison of Metabolic Syndrome 
 
 WHO(44)  
(1998) 
EGIR (36) 
(1999) 
NCEP (34) 
(2001) 
AACE(37) 
(2003) 
IDF (45) 
(2006) 
Minimum 
Criteria for 
Diagnosis 
Impaired glucose 
tolerance or diabetes 
and/or insulin resistance 
and 2 other factors 
Presence of fasting 
hyperinsulinaemia 
factors (the highest 25%) 
and 2 of the other factors 
Three or more of 
the following 
factors  
No defined number of 
risk factors is specified; 
diagnosis is left to 
clinical judgment 
Central obesity and 
2 other factors  
Glucose 
/Insulin 
abnormality 
  
Type 2 diabetes, 
impaired fasting glucose 
(FBG  ≥ 6.1mmol/l), 
impaired glucose 
tolerance (2hPPG ≥ 7.8 
mmol/l) or lowest 25% 
for hyperinsulinemic 
euglycemia clamp-
glucose uptake 
Insulin resistance 
(highest quartile of 
population) and impaired 
fasting glucose (FBG 
≥6.1 mmol/L) 
 
Impaired fasting 
glucose (FBG ≥ 
6.1 mmol/L) 
2-Hour post glucose 
challenge>140 mg/dL 
or Fasting glucose 
Between 110 and 126 
mg/dL 
Fasting glucose 
≥5.6 
mmol/L or previous 
diagnosis of 
impaired glucose 
tolerance or 
diabetes 
Obesity / 
Central 
Adiposity 
Waist: hip ratio 
>0.9 (m) 
>0.85 (f) 
and/or BMI>30 kg/m2 
Waist circumference 
>94 cm (m) 
>80 cm (f) 
Waist 
circumference 
>102 cm (m) 
>88 cm (f) 
BMI ≥ 25 kg/m2 Waist 
circumference 
≥94 cm (European 
M), ≥80 cm (F);  
≥90 cm (Asian M) 
≥80 cm (F) 
Increased 
triglyceride 
TG >1.7mmol/L TG >2 mmol/L TG ≥150 
mg/dL(1.69 
mmol/L) 
≥150 mg/dL (1.69 
mmol/L) 
TG ≥ 1.7 mmol/L 
Decreased 
HDLc 
HDL<35 mg/dL 
(0.9mmol/L)(m)  
<39 mg/dL (1.0 
mmol/L)(f) 
HDL < 1 mmol/L or on 
treatment 
HDL< 40 mg/dL 
(1.04mmol/L) (m) 
<50 mg/dL 
(1.29mmol/L)(f)  
<40 mg/dL (1.04 
mmol/L) (m) 
<50 mg/dL (1.29 
mmol/L) (f) 
<1.04 mmol/L (m) 
<1.29 mmol/L(f) 
  
Hypertension Blood pressure ≥140/ 90 Blood pressure ≥140/ 90 
or on treatment 
Blood pressure 
≥130/≥85 mmHg 
Blood pressure 
≥130/85 mm Hg 
SBP ≥ 130 or DBP 
≥ 85 or treatment 
Others Microalbuminuria 
(≥20ug/min albumin 
excretion rate or 
albumin:creatinine ratio 
≥30 mg/g) 
- - Family history of or 
high-risk ethnic group 
for diabetes, 
hypertension, CVD. 
Polycystic ovarian 
syndrome, sedentary 
lifestyle, aging 
- 
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1.3 RISK FACTORS 
1.3.1 Cardiovascular Disease 
Cardiovascular disease is identified as a multifactorial disease with risk factors that 
cluster and interact in an individual to determine the risk level. To date, no single essential factor 
has been identified; multiple interrelated factors have been demonstrated to be associated with 
the risk of CVD. Extensive clinical and epidemiological studies have identified several risk 
factors that increase the risk of coronary heart disease and stroke. Individuals with certain 
characteristics are at higher risk for CVD compared to others. Above all, older age is a factor that 
contributes to disease and cannot be changed. For example, the mortality of CHD increases with 
age; 82% of people who die from CHD are 65 or older (AHA). Being a male gender is another 
unchangeable risk factor for CHD. Men have greater risk of heart attack than women, and tend to 
develop disease in an earlier age (46, 47). However, after menopause, the risk for CHD in 
women is increased, though the mortality rate is still lower than men (48-51).  Heart disease has 
been found to be heritable, and clustered in families. Family history of CVD is not only a strong 
risk factor, but synergistic with other cardiovascular risk factors for facilitating disease 
development (52). Introduction of heritability will be discussed in the following section.  
Except for those inherent personal characteristics, CVD is related to many modifiable, 
treatable or controllable factors which could be changed by lifestyle or medication. Since 1948 
the Framingham longitudinal study has been committed to identify the common factors for CVD; 
and it has become a leader in the development and dissemination of multivariable statistical 
models to estimate the risk of coronary heart disease. As early as the 1960s, three important 
articles were published to identify five major risk factors for CHD in Framingham study (53-55). 
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In 1961, researchers found that cigarette smoking increased the risk of heart disease, the 
mortality rate of smokers was 2-3 times higher than non-smokers(53). Hypertension and 
hypercholesterol have been demonstrated to precede the development of CHD and associated 
with subsequent CHD development. High blood pressure increases the blood load and increases 
the risk for CHD 2.6-fold in men 40-60 years of age and 6-fold in women of the same age(54). 
Clearly, many clinic and epidemiological studies have demonstrated that hypertension, 
interrelated with lipids abnormalities and smoking, leads to vascular pathology and to disease 
development, which is also etiologically implicated by the epidemic of cardiovascular disease in 
developed countries decades ago(56).  
Physical inactivity and obesity were also found to be associated with CHD risk(55). 
Regular moderate-to-vigorous physical activity helps prevent heart and blood vessel disease and 
relates to adequate collateral circulation (57). People who have excess body fat are more likely to 
develop heart disease and stroke even if they have no other risk factors (57). Excessive weight 
increases the heart’s work and tends to raise the level of blood pressure, cholesterol and 
triglycerides(58), which contributes to another risk factor - diabetes. In contrast, physical activity 
can reduce the risk for type 2 diabetes by reducing insulin resistance and decreasing blood sugar 
level. In the long term, physical activity may reduce body weight and prevent adipose deposition. 
The increased demand of physical activity requires an increased glucose uptake by muscle cells, 
resulting in a reduced level of hyperglycemia(57).  
 Diabetes seriously increases the risk of developing cardiovascular disease. Diabetes and 
glucose tolerance as a risk factor for CHD have been intensively under research for decades (59-
63). It has been reported that three-quarters of people with diabetes die of cardiac disorder or 
blood vessel disease (AHA report). There are other contributing factors that are associated with 
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increased risk for CHD, but the significance has not yet been precisely determined, such as stress 
and alcohol consumption.  
1.3.2 Peripheral Arterial Disease 
The prevalence of PAD steadily increases with age. With increasing life expectancy the 
prevalence of PAD is increasing. PAD is a manifestation of diffuse and severe atherosclerosis. It 
is a strong predictor of cardiovascular disease and other atherosclerotic disorders such as 
coronary artery disease (CAD) and cerebrovascular disease (CVD) (64).  
Cigarette smoking, diabetes mellitus and advancing age are the critical risk factors. 
Smokers may have four-fold risk to develop PAD than nonsmokers. Physical inactivity is 
another risk factor of PAD that can be controlled. Studies showed that physical activity increases 
the distance that people with PAD can walk without pain and also helps decrease the risk of heart 
attack or stroke. In addition, high blood pressure and high cholesterol level contribute to build-up 
plaque, decreasing the blood flow, which eventually results in peripheral atherosclerosis. Thus, 
monitoring and controlling cholesterol level and blood pressure are essential to prevent and treat 
PAD patients (65).   
1.3.3 Chronic Kidney Disease 
The most common risk factors for chronic kidney disease (CKD) include diabetes, 
hypertension, cardiovascular disease(66), and a family history of CKD (67). Though obesity is a 
risk factor for incident diabetes, as well as cardiovascular disease, the interplay between the 
obesity and CKD has not been extensively evaluated. Recently, reports from the Cardiovascular 
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Health Study demonstrated a significant relationship between waist-to-hip ratio, but not body 
mass index (BMI), and incident CKD in a generalizable US cohort; and a significant relationship 
between waist-to hip ratio, but not BMI, with subsequent cardiovascular events and mortality 
among individuals with CKD(68). Moreover, findings from the Hisayama Study suggested that 
metabolic syndrome is a significant risk factor for the development of CKD in the general 
Japanese population (69, 70). But, such finding was not replicated in a study among a U.S. 
African American population, in which metabolic syndrome was found to be significantly 
associated with proteinuria in hypertensive African Americans, but not independently related to 
the progression of CKD(71). 
In addition, age is also a risk factor for CKD. 11% of individuals older than 65 years 
without hypertension and diabetes suffered stage 3 or worse CKD(30) compared to 0.2% in the 
age group 20 to 39 years in the NHANESIII study. Further, the Census Bureau estimates that the 
proportion of individuals aged more than 65 years will increase from 12.6% (35 million in 2000) 
to 16.5% (54 million in 2030). CKD is bringing a huge economic burden to the society. The 
important risk factors are listed in Table 1.3. Major outcomes of CKD include progression to 
renal failure, development of complications of impaired kidney function and increased risk for 
cardiovascular system disorders (32, 72).  
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Table 1.3 Major Risk Factors and Contributing Factors for CHD, CKD and MetSyn  
 
Coronary Heart Disease Chronic Kidney Disease Metabolic Syndrome 
Major risk factors that can't be changed 
Increasing age Older age Age 
Gender (male) --- --- 
Heredity (including Race) Family history of CKD Race 
Major factors that can be modified, treated or controlled by lifestyle changes or 
medication 
Obesity and overweight 
--- 
 
Abdominal obesity 
High blood cholesterol High level of proteinuria High Triglycerides, Low 
HDL cholesterol 
High blood pressure High blood pressure High Blood pressure 
Diabetes mellitus Diabetes High Fasting glucose 
Physical inactivity 
Autoimmune diseases, Systemic 
infections, Urinary tract 
infections, Urinary stones, Lower 
urinary tract obstruction, 
--- 
Tobacco smoke drug toxicity --- 
Contributing factors 
Stress Smoking  
Alcohol   
 
Major risk factors are those that research has shown significantly increase the risk of heart and blood 
vessel (cardiovascular) disease.  
Contributing factors are associated with increased risk of cardiovascular disease, but their significance 
and prevalence haven't yet been precisely determined. 
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1.3.4 Diabetes 
The clinical risk factors for type 2 diabetes include the following conditions: age, obesity, 
physical inactivity, race/geographical location, family history of diabetes and previous 
gestational diabetes. The major risk factors have been known for several years, such as obesity, 
sedentary lifestyle and genetic predisposition. These have been consistently implicated in among 
all studies in various populations.  
Substantial evidence supported that obesity and weight gain were associated with 
increased risk of diabetes(73-75), and that weight loss reduced the risk of overweight people to 
develop diabetes(75). Obesity is commonly measured by body mass index (BMI), which 
averages the mass of an individual over an estimate of body area, in epidemiologic studies. 
However, body surface and measures of abdominal adiposity such as BMI and waist 
circumference, do not capture the relative contribution of subcutaneous and visceral fat to the 
total measure(76). Not only the amount of adipose tissue an individual has contributes to disease, 
but also where the fat is deposited. The most important distinction is whether it is deposited 
around/within the abdomen, typically seen in males, or along the hips and thighs, which is 
typically observed in females. To determine if individuals have an increased risk for disease due 
to fat distribution, waist to hip ratio has been used, with a ratio of greater than 1.0 in men and 0.8 
in women putting individuals at higher risk respectively.  
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1.4 CYSTATIN C  
Cystatin C is a non-glycated basic protein with a small molecular weight of 13.3 Kda. It 
belongs to the super family of cystatins, and it functions as a cysteine proteinase inhibitor (77). 
Unlike creatinine, which is a by-product of muscle cells and affected by many other factors than 
kidney disease, cystatin C is produced by all nucleated cells and excreted into the bloodstream at 
a constant level without impact of age, gender, race and muscle mass (78, 79). 
1.4.1 Biomarker for Kidney Function 
Glomerular filtration rate (GFR) is the gold standard measurement for kidney function, 
and widely accepted as the best overall test of kidney dysfunction. It is determined by the 
clearance of inulin or iothalamate, which is believed to be an ideal filtration marker since it is 
excreted from the body only through kidneys and fully excreted via glomerular filtration. 
However, the direct measurement of these clearances is cumbersome, requiring considerable 
time, money and is not easily implemented in daily clinic practice(80). To circumvent these 
drawbacks, the series of equations based on a traditional biomarker- serum creatinine provide the 
estimation of kidney function and has been widely used. The independent international Kidney 
Disease Improving Global Outcome organization (K/DOQI) provides two recommendations for 
detecting CKD: (1) eGFR as the best estimation of kidney dysfunction based on the simplified 
equation derived from the Modification of Diet in Renal Disease Study(MDRD): GFR [mL · 
min-1 · (1.73 m2) -1] = 175 × (serum creatinine [mg/dL]-1.154× age [years] -0.203[× 0.742, if female] 
[× 1.212, if African American](81); and (2) determination of proteinuria, preferably 
microalbuminuria, corrected for urine creatinine (77). However, using serum creatinine as a 
24 
 
measurement to estimate GFR has several drawbacks, including  the ‘creatinine-blind range’, 
which limits the utility of serum creatinine in detection of slight to moderate renal dysfunction 
(77) and some technical issues in assay measurements(77). Furthermore, serum creatinine is 
affected by other factors such as muscle mass, dietary intake, aging, and race(82). Due to these 
inconsistencies in serum creatinine estimation, the National Kidney Foundation concluded that 
serum creatinine should not be solely used to assess the level of renal function (83).  
Cystatin C is an alternative measurement of kidney function and a large number of 
studies have shown that estimated glomerular filtration rate (eGFR) based on Cystatin C is 
superior to such estimation based on multiple serum creatinine measures (84). Numerous studies 
found that cystatin C levels were more accurate to predict GFR in various clinical presentations, 
especially in mild to moderate kidney disease patients (with a relatively higher eGFR)(85). Vikas 
et al conducted a meta-analysis and showed that cystatin C level is a significantly better 
biomarker of kidney function; they detected higher correlation coefficients between GFR and the 
estimated GFR based on cystatin C than serum creatinine(82).  Zaharan et al collected 14 studies 
in kidney transplant patients and 29 studies among patients with native kidney disease to 
compare the performances of cystatin C vs. creatinine. The results demonstrated that 70% of 
studies performed on transplantation favored cystatin C, and 85% studies performed in native 
renal diseases showed a superiority of cystatin C based eGFR equations (86). Anders Grubb et al 
found a simple cystatin C based prediction equation for eGFR using only cystatin C 
concentration in mg/l and a prepubertal factor, if applicable, which is believed to perform equally 
well or better than the simplified MDRD formula (87).  
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1.4.2 Biomarker for Cardiovascular Risk 
Cystatin C reflects inflammation, and is found to be related to C-reactive protein, which 
accounts for the association with cardiovascular disease (88). Many studies searched for such a 
relationship, and compared the performance between cystatin C and serum creatinine (89-93). 
Among these, some studies have examined the racial difference in association. Bibinns-Domingo 
et al conducted a community based study, of 1124 black and 1676 white adults. They found a 
stronger association between kidney dysfunction and heart failure among blacks than among the 
white population when using cystatin C as a biomarker (94).  
Cystatin C was also found to be related to subclinical measurements for CVD. Results 
from Cardiovascular Health Study (CHS) indicated that elevated concentration of cystatin C was 
an independent predictor for incident PAD among elderly patients. The hazard ratio for 
participants with highest cystatin C (> 1.27 mg/L) was as high as 2.5 [95% confidence interval, 
1.2 – 5.1] compared to those whose cystatin C level < 0.90 mg/L(95).  Further, cystatin C was 
found to be related to arterial stiffness; a positive relationship between baPVW and cystatin C 
has been found independently of serum creatinine and eGFR among both men and women in a 
general Korean population(96). It will be meaningful to conduct such an association study 
among participants of African descent, since no similar studies have been reported among 
African Americans who are at much higher risk for cardiovascular disease. The proposed 
research will address this gap. 
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1.5 HERITABILITY  
Heredity, as a risk factor, has been studied more extensively recently. Although the 
environmental factors have been established for decades, more recently, a number of genes have 
been reported to be associated with heart disease, stroke and high blood pressure in large 
population-based studies. A Danish twin study, including 1209 monozygotic and dizygotic twins, 
has found a substantial genetic influence on individual susceptibility to CHD after controlling for 
smoking and body mass index(97). Another large scale long term twin study conducted in 
Sweden, has also found a moderately large genetic variation in susceptibility to death from CHD. 
The heritability was 0.57 (95% CI, 0.45–0.69) amongst male twins, and 0.38 (0.26–0.50) 
amongst female twins(98). Regarding the subclinical cardiovascular measurement, the 
heritability of ankle brachial index (ABI), estimated in a Caucasian population, the Framingham 
Offspring Study, was about 27% (12).  However, such findings have not been replicated in 
various ethnicity groups, especially among African American population, who were at higher 
risk for cardiovascular and renal disorders. Pulse wave velocity (PWV), which is a measurement 
of arterial stiffness, has also been confirmed to be heritable. The estimated heritability of radial 
and foot PWV was 0.43 and 0.53 respectively, without a detected difference between racial and 
gender groups(99).     
Further, it has been established that genetic factors play a role in the progression of 
kidney disease; GFR and urinary albumin excretion (UAE) are known to be heritable. A recent 
genome-wide association study for kidney function has found that four SNPs were highly 
associated with serum cystatin C levels in whites (100). Although inheritance is a recognized 
determinant of cystatin C and kidney dysfunction, little is known about the genetic contributions 
to renal dysfunction in families of African descent. In addition to its relationship with renal 
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function, cystatin C has been reported to be associated with CVD risk factors among participants 
without chronic kidney disease. Cystatin C was a significant heritable trait with the 
multivariable-adjusted heritability of 0.35 (p <0.001) in Framingham Offspring Study(101). It 
will be worthwhile to test the heritability of cystatin C in African Tobago population to inform 
future genetic studies to identify the loci related to kidney dysfunction in African individuals. 
Metabolic syndrome, together with all its components, has been reported to be heritable. 
The Northern Manhattan Family study has documented the heritability of MetSyn, using ATP III 
definition itself, to be 24%, with significant heritability for lipid/glucose/obesity (44%) and 
hypertension (20%) among Caribbean-Hispanic families (11). Evidence for a genetic basis to 
type 2 diabetes includes family clustering of insulin sensitivity(102). Twin studies provided 
further evidence for genetic factors contributing to type 2 diabetes(103). There are many 
potential ‘diabetic genes’, such as candidate genes involving in regulating the secretion and 
action of insulin which may contribute to the disease development as reviewed by Permutt et 
al(104). However, no convincingly significant variations have been found among those genes 
investigated.   
Furthermore, genetic association studies, by using case-control, cohort or family-based 
studies, relate genetic factors to heritable phenotypes. For example, ADIPOQ is one of the 
adipokine candidate genes. Its SNP276 has been found to be related to the reduced risk of 
obesity among Taiwanese individuals(105). And the adiponectin gene I164T polymorphism 
could be a stronger determinant of abdominal obesity with lower serum adiponectin levels 
among Japanese women(106). WNK4 (PRKWNK4) genes cause familial hypertension known as 
pseudohypoaldosteronism type II, which has been found to be involved in the development of 
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hypertension in Japanese general population(107). Thus, the variations associated with individual 
component phenotype could underlie an association with metabolic syndrome.  
Although genetics play a critical role in the development of metabolic syndrome, genetic 
studies thus far provided conflicting association rather than consistent evidence. The apparent 
heritability of metabolic syndrome reflects the heritability of the individual risk factors included 
in the definition of metabolic syndrome. The dominance of each risk factor in the designation of 
metabolic syndrome differs across the ethnic/gender population, which explains the observed 
inconsistent heritability. The context-dependent factors, such as ethnicity, diet and gender could 
confound the association and affect the pathogenesis of the metabolic syndrome(108).  
1.6 TOBAGO HEALTH STUDY POPULATION 
Tobago is the smaller of the two main islands that make up the Republic of Trinidad and 
Tobago. It is located in the southern Caribbean Sea, northeast of the island of Trinidad and 
southeast of Grenada.  
Tobago has a land area of 300 km² (116 mi²), and is approximately 42 kilometres (26 
Miles) long and 10 kilometres (6 miles) wide. It is located at latitude 11° 9' N, longitude 60° 40' 
W, slightly north of Trinidad. The population is 54,084 (2000). The capital is Scarborough, with 
a population of about 17,000. While Trinidad is multiethnic, the population of Tobago is 
primarily of African descent, although with a growing proportion of Trinidadians of East Indian 
descent and Europeans. Tobago population is at high risk of chronic diseases such as 
hypertension, diabetes, cardiovascular disease and impaired kidney function. WHO statistics for 
Trinidad & Tobago document the highest rate of death due to CVD of any country outside the 
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former Soviet block. Furthermore, they live in a relatively isolated island with less westernized 
life style, are physically active, less fat intake and less medication intervention. Their genetic 
background is relatively homogenous compared to African Americans. A previous study based 
on ancestry informative markers  estimated that older residents are 94% of West African origin 
(109).  This population provides a special opportunity to look at the genetic impact of West 
African descent on the complex diseases.  
The Tobago Family Health Study was initiated in 2003 by Dr. Joseph Zmuda as Principal 
Investigator.  To be eligible, a proband must have been Afro-Caribbean, have had a spouse who 
was willing to participate in the study and have at least six living offspring and/or siblings aged 
18+ years who were residing in Tobago.  To date, 471 individuals, aged 18-103 years, are 
enrolled in this study. They belong to seven, multi-generation Afro-Caribbean families (mean 
family size 51 individuals) on the Tobago Island (Figure 1.3). Among these individuals, we have 
the 3535 relative pairs, including 361 parent-offspring, 495 full sibling, 101 grandparent-
grandchildren, 1137 avuncular, 61 half sibs and 1380 cousins. The complete data for current 
analysis was available in 402 individuals. Written informed consent was obtained from every 
participant, using forms and procedures approved by the Tobago Division of Health and Social 
Services, and the University of Pittsburgh, Institutional Review Boards. 
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Figure 1.3 Map of Tobago Island  
(The figure was adopted from the reference (110)) 
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1.7 SUMMARY 
Familial aggregation of major complex diseases is well known, and cardiovascular 
disease and chronic kidney disease have been reported to be heritable in previous studies(111). 
As a novel renal function biomarker, cystatin C was reported to be 35% heritable in the 
Framingham Offspring Study. The Northern Manhattan Family study has documented that the 
heritability of MetSyn was 24%, with significant heritability for lipid/glucose/obesity (44%) and 
hypertension (20%)(11). No previous study of metabolic syndrome or chronic kidney disease 
was published among African Caribbean populations. The proposed research will be the first to 
investigate the heritability estimation among multigenerational African Caribbean families, who 
are 94% of West African origin (109). The project will provide first hand evidence of disease 
occurrence as well as the heritability of metabolic traits among African Caribbeans which will 
benefit future studies.  
In addition to estimating heritability, we are proposing to explore the association between 
renal function and subclinical cardiovascular disease, which process in the cardiovascular system 
starts many years before life-threatening events occur. With current techniques, subclinical CVD 
can be measured noninvasively and sensitively by the following laboratory examinations. (1) 
Pulse wave velocity (PWV) is a well established technique for evaluating arterial stiffness, or 
arteriosclerosis (18-20) and also is a marker for atherosclerosis (21-24). (2) Carotid intima-to 
medial wall thickness (IMT), a common assessment for atherosclerosis, is measured by B-mode 
Ultrasound examination of the carotid arteries. (3) Ankle brachial index (ABI), evaluated by a 
simple ratio of systolic blood pressure over the ankle and arm is a simple assessment for 
peripheral arterial disease.   
32 
 
Cystatin C is a novel biochemical marker for kidney function and has been reported to be 
superior to serum creatinine in estimating GFR(84). In addition, elevated cystatin C level is 
related to baPWV (96),  peripheral arterial disease(95) and cardiovascular disease in absence of 
impaired kidney function(101). However, no previous study has comprehensively studied the 
association of renal function, with subclinical cardiovascular disease assessed by three 
measurements, in a population of African descent. The proposed study will fill the gap and 
become the first to conduct such association study among African descendants who are regarded 
to reflect the general healthy population on the Island of Tobago.  
 
 
 
 
 
 
 
33 
 
2.0 HERITABILITY OF KIDNEY FUNCTION BIOMARKERS IN AFRO-
CARIBBEAN FAMILIES  
H Li,1 M.B.B.S., CH Bunker1,Ph.D.,  AL Patrick3, MD, FRCP,  LH Kuller1,M.D., Dr.Ph., 
CM Kammerer2, Ph.D., I Miljkovic1,M.D., Ph.D.,  VW Wheeler3, MBBS, MRCOG,  JM 
Zmuda1,2, Ph.D. 
Departments of Epidemiology1 and Human Genetics2, Graduate School of Public Health, 
University of Pittsburgh, Pittsburgh, PA; 3The Tobago Health Studies Office, Scarborough, 
Tobago, Trinidad & Tobago 
 
Email: ZmudaJ@edc.pitt.edu 
 
  
34 
 
2.1 ABSTRACT 
Objectives: Kidney disease is a prevalent clinical and public health problem among individuals 
of African ancestry. We assessed the prevalence and heritability of kidney function in families of 
Afro-Caribbean ancestry. Design and Methods: Serum creatinine and urinary microalbumin 
were measured in 402 adults from 7 large, multi-generation pedigrees (average family size: 50; 
range: 19 to 96; 3535 relative pairs) comprising a total of 402 Afro-Caribbean individuals, aged 
18 to 103 years. Estimated glomerular filtration rate (eGFR, MDRD formula) and age-specific 
prevalence of decreased eGFR were calculated and compared to African Americans in the U.S. 
Heritability (h2) was estimated with maximum likelihood methods using SOLAR (Sequential 
Oligogenic Linkage Analysis Routines). Results: The age standardized mean serum creatinine 
was 1.03 ± 0.01 mg/dL for Afro-Caribbean men and 0.82 ± 0.01 mg/dL for Afro-Caribbean 
women. Creatinine was significantly higher among older, diabetic and hypertensive participants. 
The eGFR was 100.6±23.9mL/min per 1.73 m2 in men and 96.7±27.4 in women, decreased 
across age groups and was significantly lower in diabetic, hypertensive and obese participants. 
The age standardized prevalence of decreased eGFR (eGFR < 60 [mL · min-1 · (1.73 m2) -1]) was 
8.9% among Afro-Caribbeans.  Additive genetic effects accounted for: 28% of the variation in 
serum creatinine (P<0.0001) adjusted for age, sex, anti-hypertensive treatment and low density 
lipoprotein cholesterol; 22% (P<0.0001) of the variation in urinary albumin, adjusted for gender, 
and systolic blood pressure (SBP); and 19% (P=0.0007) of the variation in urinary albumin to 
creatinine ratio, adjusted for gender, fasting glucose and SBP. Conclusion: A high prevalence of 
decreased eGFR was found in this relatively young sample of Afro-Caribbeans, which was 
associated with a high prevalence of hypertension and diabetes. Additive genetic effects 
accounted for a significant fraction of residual variation in several indices of kidney function. 
35 
 
Additional research is needed to identify the genetic factors which contribute to the high risk of 
kidney dysfunction in this Afro-Caribbean population.  
Keywords: serum creatinine, renal dysfunction, heritability, Afro Caribbean, age standardized 
prevalence 
2.2 INTRODUCTION 
Chronic kidney disease (CKD) is a major public health problem, and is particularly 
prevalent among populations of African ancestry. Kidney dysfunction is associated with 
considerable morbidity including hypertension(112, 113), type 2 diabetes(114-116), 
cardiovascular disease(117), and increased risk of death(117). According to the NHANES III 
Survey, 5.5 million Americans have impaired kidney function, and more than 650,000 patients in 
the U.S. alone may require dialysis in 2010(83). Comparisons between African Americans and 
Caucasians indicate that the incidence of end stage renal disease (ESRD) related to diabetes is 
four times higher than that of Caucasians, and the prevalence of ESRD due to hypertension is 
two-fold higher than that of Caucasians(118). Chronic renal failure continues to be a major issue 
among African ancestry individuals living in other geographic regions such as the Caribbean 
(119), as it is internationally(120). 
In 2002, the Kidney Disease Outcomes Quality Initiative (K/DOQI) of the National 
Kidney Foundation (NKF) defined CKD as either kidney damage, as evidenced by albuminuria, 
or by a glomerular filtration rate (GFR) below 60 ml/min/1.73 m2 for ≥ 3 months irrespective of 
the cause (121). Serum creatinine is the most widely used measure of the presence and 
progression of CKD(122). The Modification of Diet in Renal Disease Study (MDRD) and the 
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Cockcroft Gault (CG) equations are the most frequently used assessments of the prevalence of 
CKD(123). These indirect estimates of GFR are critically dependent on the calibration and 
validation of the serum creatinine assay(124). The MDRD equation may outperform the CG 
equation (125) and has been applied in many epidemiological studies to investigate disease 
burden, such as Third National Health and Nutrition Examination Survey (NHANES III) in the 
U.S(81). However, serum creatinine concentration is influenced by many factors, including 
skeletal muscle mass, dietary intake, secretion by renal tubules and by some medications (126).  
Previous epidemiological studies have reported that CKD may cluster in families, 
suggesting a genetic predisposition(127). CKD related traits such as elevated serum creatinine, 
serum creatinine clearance rate, eGFR and albuminuria are all highly heritable (128-130) in 
European ancestry individuals.  Genome-wide linkage scans have detected chromosomal regions 
that may harbor CKD susceptibility loci (111).  Other recent studies have identified MYH9 as a 
possible candidate gene for CKD among African Americans (131, 132). TCF7L2 alleles have 
also been related to reduced kidney function and CKD progression in both Caucasian and 
African ancestry individuals (133). However, the higher prevalence of CKD among persons of 
lower socio-economic status suggests that environmental factors may also contribute to this 
disease(127). Thus, a complex interplay between genetic and environmental factors plays a role 
in CKD.  
The Afro-Caribbean population of Tobago is predominantly of West African origin. 
Previous studies using ancestry informative molecular markers have documented  lower 
admixture (6% non-African) in this population compared with African Americans(109). In 
Trinidad and Tobago, 20 % of renal failure occurs among the working age population (119). 
Studies in other populations of African descent have documented an elevated prevalence of risk 
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factors for CKD such as diabetes mellitus and hypertension(119). However, to our knowledge, 
there is no estimation of the prevalence of decreased eGFR and albuminuria in African ancestry 
populations living in the Caribbean. The purpose of this study was to estimate the prevalence and 
heritability of renal impairment among Afro-Caribbeans living in Tobago.  
2.3 METHODS 
2.3.1 Study Population 
The current study was conducted in 402 individuals aged 18 – 103 years (mean age 42 
years) belonging to seven, multi-generation Afro-Caribbean families (mean family size 51 
individuals) on the Tobago Island (99). Briefly, to be eligible, a proband must have been Afro-
Caribbean, have had a spouse who was willing to participate in the study and have at least six 
living offspring and/or siblings aged 18+ years who were residing in Tobago. Participants were 
recruited without regard to health status. Among these individuals, there are 3,535 relative pairs, 
including 361 parent-offspring, 495 full sibling, 101 grandparent-grandchildren, 1137 avuncular, 
61 half sib and 1380 cousin pairs. Complete data on kidney function measures for current 
analysis was available in 402 individuals. Written informed consent was obtained from every 
participant, using forms and procedures approved by the Tobago Division of Health and Social 
Services, and the University of Pittsburgh, Institutional Review Boards. 
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2.3.2 Covariate Measurements 
Information on demographic characteristics, medical history, and lifestyle habits was 
obtained by questionnaire and interview by trained and certified staff. Race/ethnicity was based 
on self-declaration, and participants provided detailed information on the ethnic origin of their 
parents and grandparents. Respondents were assigned to an ethnic group if they reported that all 
four grandparents belonged to that group. Subjects were classified as current smokers (yes/no). 
Participants who had smoked <100 cigarettes in their lifetime were considered nonsmokers. 
Information on alcohol consumption was obtained by questionnaire and expressed as drinks per 
week. Subjects were asked if they walk for exercise (yes/no). Physical activity was also assessed 
as a continuous variable by the number of minutes walked, and physical inactivity as the hours 
spent watching television per week. Participants were asked to bring prescription medications to 
the clinic for verification. Current use was defined as use within the preceding 30 days. A study-
specific medication dictionary was used to categorize the type of medication from product brand 
and generic names obtained from the medication containers. Blood pressure was measured three 
times using an automated blood pressure machine (Omron model HEM-705CP, Illinois). The 
average systolic blood pressure and diastolic blood pressure was calculated based on the average 
of second and third measurements. Metabolic traits, including triglyceride, total serum 
cholesterol level, low density cholesterol (LDL), high density cholesterol (HDL), fasting insulin 
and fasting glucose, were measured with standard protocols. 
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2.3.3 Serum and Urine Sample Collection 
Blood samples were obtained by venipuncture in the morning after a 12-hour fast. Whole 
blood sat at room temperature for a minimum of 20 min to clot before centrifugation. A spot 
urine sample was also collected. Aliquots of serum and urine were frozen at -20°C locally and 
shipped on dry ice to the University of Pittsburgh by express courier within a month where the 
samples were stored at -80 °C. 
2.3.4 Laboratory Measurements 
Serum creatinine was quantitatively determined by the VITROS CREA Slide method. 
The sample was diluted with VITROS 7% BSA. Standards, serum controls and duplicate 
samples were run with each assay, which were traceable to a Gas Chromatography Isotope 
Dilution Mass Spectrometry (GC/IDMS) method and National Institute of Standards and 
Technology (NIST) SRM®914 creatinine standard reference material. Creatinine values 
traceable to this standard, and the results, are referred to as standardized creatinine values.  Urine 
samples were diluted with 1:1 reagent-grade water, and urinary creatinine was analyzed as 
above. 
 Albumin in urine was measured using a turbidimetric procedure on the Olympus AU400 
using reagents provided by Olympus America, Inc. (Center Valley, PA).  10 µl of urine was 
incubated with goat anti-human albumin antibody for 5 minutes at room temperature. The 
resulting turbidity was measured at 340/800 nm.  The procedure was linear from 0.5 – 30 mg/dL. 
Blanks, calibrators and control pools were run simultaneously with all samples.  The intra- and 
inter-assay coefficients of variation were below 2.5% and 5.1%, respectively. 
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2.3.5 Disease Definition 
Hypertension was defined as diastolic blood pressure >90 mmHg, systolic blood pressure 
≥140 mmHg, or currently taking blood pressure medication (134). Diabetes was defined as 
fasting glucose level ≥126 mg/dl or currently taking diabetes medication(135). Obesity was 
defined as BMI ≥ 30 kg/m2. Chronic kidney disease (CKD) was defined as eGFR based on 
creatinine (eGFR < 60 mL/min per 1.73 m2)(83).  The spot albumin-to-creatinine ratio (ACR) 
was calculated and reported in milligrams per gram. According to the American Diabetes 
Association (ADA) (136) and National Kidney Foundation(137), albuminuria was defined as 
ACR > 30 mg/g; microalbuminuria: 30-299 mg/g and macroalbuminuria: ≥300 mg/g. 
2.3.6 Statistical Methods 
Before analysis, the distributions of serum creatinine, urinary albumin and urinary 
creatinine were assessed for normality. Outliers (defined as ±4 SD) were removed from further 
analyses. No more than four values were removed for a single variable. The simplified 
Modification of Diet in Renal Disease Study (MDRD) equation was used to estimate glomerular 
filtration rate based on serum creatinine: GFR [mL · min-1 · (1.73 m2) -1] = 175 × (serum 
creatinine [mg/dL]-1.154× age [years] -0.203[× 0.742, if female] [× 1.212, if African American] 
(81). Age was included in years and serum creatinine in mg/dl.  
The age-specific prevalence of decreased eGFR and the age-specific standardized serum 
creatinine concentration for African Americans in the U.S. were calculated from the NHANES 
III 2005-2006 publicly available dataset (http://www.cdc.gov/nchs/nhanes/nhanes2005-
2006/quex05_06.html). Serum creatinine concentration was standardized using an established 
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formula: Standardized creatinine (mg/dL) = -0.016+0.978*(NHANES 05-06 uncalibrated serum 
creatinine, mg/dL) (138). We compared the age-adjusted prevalence of impaired kidney function 
in the Afro-Caribbeans with that observed in African Americans in NHANES III by direct age 
standardization with the U.S 2000 standard population.(139).  The age-adjusted mean 
concentration of serum creatinine was calculated using standard age groups based on the U.S. 
2000 standard population, accounting for the unequal probability of sampling or non-
response(140).  The analyses were performed in SAS (SAS Institute Inc., SAS® 9.2).  
The heritability of renal function measures was assessed in SOLAR (Sequential 
Oligogenic Linkage Analysis Routines), after removing the effects of significant covariates. The 
covariates were evaluated first using multivariate linear regression modeling at a significance 
level of <0.10. Second, potential covariates were evaluated using a variance component approach 
implemented in SOLAR, which accounted for the effects of relatedness of family members. 
Briefly, the variance components approach involves partitioning the variance of a quantitative 
trait into components attributable to individual-specific covariates, an additive genetic 
(polygenic) component and a residual non-measured environmental component. The significance 
of a particular independent variable (e.g., fasting glucose) was assessed by the likelihood ratio 
test, which compared the likelihood of a full model (e.g., age, BMI, and fasting glucose) to that 
of a nested model (e.g., age and BMI only, with the glucose effect constrained to be zero). 
Residual heritability was calculated as the proportion of the total phenotypic variance explained 
by additive genetic effects after accounting for covariates.  
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2.4 RESULTS 
2.4.1 Characteristics of Study Participants 
Characteristics of the 402 family members are shown in Table 1. BMI and obesity were 
higher (p < 0.001) in women than men, but waist circumference was similar.  Prevalence of 
cigarette smoking and alcohol consumption was higher among men than women. The prevalence 
of hypertension and diabetes was similar in men and women. 
2.4.2 Serum Creatinine by Age and Gender 
Serum creatinine was not normally distributed. Among all family members aged 18 years 
and older, the median serum creatinine level was lower in women (0.81 mg/dL) than in men 
(1.01 mg/dL). The mean concentration of serum creatinine increased with age in both men and 
women (Table 2). Serum creatinine levels were significantly elevated in persons 40 years or 
older among both genders compared with those aged less than 40 years. 
The age-adjusted standardized mean serum creatinine level was 1.03 ± 0.01 mg/dL for 
Afro-Caribbean men and 0.82 ± 0.01 mg/dL for Afro-Caribbean women. The age-adjusted 
calibrated serum creatinine level for African Amercian men was 1.14 ±0.04 mg/dL and 0.83 ± 
0.02 mg/dL for African American women in the U.S. NHANES III (138). The mean serum 
creatinine level was adjusted for age groups based on the U.S. census standard population for the 
year 2000 (141). The comparison between Afro-Caribbeans and the U.S. black population 
indicates that Afro-Caribbean men have lower creatinine levels than U.S. blacks; but Afro-
Caribbean women have higher levels than U.S. black women (data not shown). 
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2.4.3 Estimated GFR by Age and Gender 
The estimated GFR calculated using the simplified MDRD equation was 98.2 [mL · min-1 
· (1.73 m2) -1] (SD: 26.13) in the total sample (Table 2). Men had higher eGFR compared to 
women except in the youngest age group (<20 years). Altogether, 27 participants had eGFR less 
than 60 [mL · min-1 · (1.73 m2) -1]: 24 (19 women and 5 men) had eGFR between 30 and 60 [mL 
· min-1 · (1.73 m2) -1]; and 3 women had eGFR less than 30 [mL · min-1 · (1.73 m2) -1]. 
2.4.4 Prevalence of Decreased eGFR and Albuminuria 
The prevalence of decreased eGFR increased with age among Afro-Caribbean men and 
women. For example, the prevalence of decreased eGFR was 0.6% among Afro-Caribbeans aged 
20 to 39 years, 2.1% among those aged 40 to 59 years, 23.8% among those 60 to 70 years and 
41.9% among those who were older than 70 years (Table 3). The age-standardized prevalence of 
decreased eGFR among Afro-Caribbeans in Tobago was 8.9% ±1.4%, which was higher than 
that in U.S African American population, estimated in NHANES III (6.9% ±0.8) (Table 3), 
although this difference did not reach statistical significance. 
Afro-Caribbean women had significantly higher urinary albumin and ACR compared to 
Afro-Caribbean men (p <0.0001). Table 4 shows the age-specific distribution of ACR. The 
prevalence of albuminuria (both micro- and macro- albuminuria) increased with age, and was 
higher in women compared to men in each corresponding age group. Overall, the age 
standardized prevalence of albuminuria was lower in Afro-Caribbeans than African Americans 
NHANES III in 2005-2006 (9.2% ±1.5 vs. 14.5% ±1.2) (Table 4).  However, Afro-Caribbean 
44 
 
women aged 60 and above appeared to have worse kidney damage compared to African 
American women of similar age.  
2.4.5 Heritability of Kidney Function 
Serum creatinine, urinary albumin and urinary albumin to creatinine ratio were all 
significantly heritable in these Afro-Caribbean families (Table 5). Age, sex, anti- hypertensive 
medication use (yes/no), serum LDL-C level, diabetes status (yes/no) and smoking status 
(yes/no) were considered as potential covariates of serum creatinine. After accounting for family 
relatedness, diabetes (p=0.23) and smoking status (p=0.08) were not significantly correlated with 
serum creatinine. The residual heritability of serum creatinine was 0.28 ± 0.10 (P<0.0001), 
simultaneously adjusting for age, sex, anti-hypertensive treatment and serum LDL-C (all 
covariates had P<0.01). Sex, fasting glucose and systolic blood pressure were considered as 
potential covariates for urinary albumin. The residual heritability of urinary albumin was 22% 
(P=0.0006) after simultaneously accounting for sex and systolic blood pressure. The additive 
genetic effects accounted for 19% (p=0.0007) of the urinary albumin to creatinine ratio, after 
adjusting for sex, glucose and systolic blood pressure. Body mass index and alcohol 
consumption were not related to any of the renal function measures.  
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2.5 DISCUSSION  
The age standardized prevalence of decreased eGFR was 8.9% (±1.4) among Afro-
Caribbeans and 6.9% (±0.8) among African Americans. A higher proportion of Afro-Caribbeans 
had decreased eGFR compared to African Americans, but the difference did not reach statistical 
significance due to the relatively small sample of Afro-Caribbeans. Kidney function decreased in 
a similar pattern among African Americans and Afro-Caribbenas until they reached age of 60. 
After age 60, Afro-Caribbeans had worse kidney function especially among women.  
As reported previously (142), we found increased age and female gender were 
significantly and positively related to CKD. No participants had low eGFR before age 20 years 
whereas kidney function was dramatically decreased after age 40 years. As in the U.S., 11% of 
individuals older than 65 years without hypertension or diabetes had stage 3 or higher CKD(30) 
compared to 0.2% in the age group 20 to 39 years. Kidney damage, as reflected by 
microalbuminuria or macroalbuminuria, was also more prevalent among the older age groups. 
Compared to men, decreased kidney function was much more prevalent among women. The 
underlying reasons accounting for this gender difference are unclear. A possible explanation 
could be the higher prevalence of hypertension and diabetes among Afro-Caribbean women 
compared to men aged 60 and older in Tobago (data not shown). Both hypertension and diabetes 
are associated with decreased renal function and albuminuria (142).  
In addition to reflecting creatinine excretion by the kidneys, serum creatinine is affected 
by other factors such as muscle mass(143), dietary intake, aging, secretion by renal tubules(144), 
and race(82). Differences among clinical laboratories in the calibration of serum creatinine may 
account for as much as a 20% error in the eGFR, especially among individuals with mild 
impaired kidney function(145). Due to these inconsistencies in serum creatinine measurement, 
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the National Kidney Foundation concluded that serum creatinine should not be solely used to 
assess the level of renal function (83). Current guidelines for detecting CKD recommend the use 
of eGFR from serum creatinine measurements using prediction equations such as MDRD and 
Cockcroft–Gault (145). Compared to the Cockcroft-Gault equation, MDRD has been reported to 
be more accurate and precise. The MDRD equation was developed in a large dataset (n>1000) 
that included both black and white individuals and was validated in an additional 500 
patients(146). However, in addition to assumptions of similar muscle mass between populations, 
using serum creatinine to estimate GFR has several technical issues (77), which limits its use for 
detecting slight to moderate renal dysfunction (77). Also, there is concern regarding the 
application of the MDRD equation to different populations.  Population-specific correction 
factors for CKD may be more appropriate. For example, the original MDRD equation has been 
modified with different coefficients when applied to the Japanese or Chinese population (147, 
148). Even though MDRD has a correction coefficient for the African American population, the 
adjustment for gender and ethnicity might not be sufficient for Afro-Caribbeans. Body 
composition studies have found a higher proportion of lean muscle mass to total body mass in 
Afro-Caribbean men compared with U.S. men(149). Thus, the MDRD formula may not be 
appropriate for use in this population with high muscle mass, since the MDRD formula may 
overestimate impaired kidney function in Afro-Caribbean men, but not in women.   
Our data suggest that the age adjusted mean standardized serum creatinine level in Afro 
Caribbean men was lower than the African American men, but higher in Afro-Caribbean women 
than the African American women. As in other populations, higher mean serum creatinine level 
was observed in men compared to women in each age group, which may be attributable to 
greater muscle mass in men. Ethnic differences in creatinine distribution have been reported in 
47 
 
the U. S. previously; non-Hispanic blacks have higher levels, and Mexican Americans have 
lower levels compared to Caucasians (126). However, the underlying reasons for such 
differences among ethnic groups are unknown. The differences may be the result of 
physiological differences such as muscle mass, renal tubular structure, or the different 
consequences of hypertension and diabetes.  
Our analyses revealed a significant heritability of renal function measures in multi-
generational Afro-Caribbean families. There are limited data on the heritability of renal function 
in blacks. Our findings support a significant genetic contribution to renal function in Afro-
Caribbeans for serum creatinine, urinary albumin and the albumin to creatinine ratio.  The 
heritability of serum creatinine in the Framingham Heart Study offspring cohort, in which 1224 
Caucasian individuals from 330 families were analyzed, was 0.29 (128). A highly significant 
heritability for kidney function has also been found in diabetic(130), hypertensive (150, 151) and 
Hispanic individuals (152). Furthermore, previous genome wide linkage scans have found 
suggestive evidence (LOD score > 2) for loci linked to kidney function on chromosomes 2 (153), 
3 (128) and 4(128). Thus, our significant heritability estimates of serum creatinine, eGFR and 
urinary albumin in families of African ancestry confirm a familial aggregation of renal function 
and justify further analyses aimed at understanding the genetic determinants of renal function in 
this high risk ethnic group. 
Our study has potential limitations. Firstly, our definition of CKD relied on eGFR, rather 
than direct measurements of GFR. Equations for estimating GFR have limited precision and 
accuracy compared with directly measured GFR, especially among persons with mild kidney 
impairment.  Our sample size was also relatively small.  In addition, we estimated eGFR and 
prevalence of CKD from seven multigenerational families. The probands and family members 
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were recruited without regard to their health status and all participants were ambulatory.  
Therefore, we may have underestimated the prevalence of impaired kidney function in this 
population. Nonetheless, the data provide preliminary estimates of the prevalence of impaired 
kidney function in this Afro-Caribbean population. 
In conclusion, among these African ancestry families, the serum concentration of 
creatinine and the age standardized prevalence of decreased eGFR were higher than in the 
African American population. The significant heritability of serum creatinine, eGFR and urinary 
albumin indicate a familial aggregation of these traits and justify future efforts to understand the 
genetic determinants of renal dysfunction in Afro-Caribbeans.  
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Table 2.1 Demographic Characteristics of Afro-Ccaribbean Family Members 
 
Characteristics Men Women 
N 156 246 
Age (Mean ± SD) 42.1±16.9 42.6±17.3 
Anthropometric (Mean ± SD) 
BMI  26.7±5.1 29.2±7.0 *** 
Height 177.2±7.3 166.6±6.5 *** 
Weight  84.1±17.9 81.1±19.6 
Waist  90.2±12.7 89.8±17.3 
Lifestyle Characteristics  
Current Smoking N (%)  17 (11.0) 1 (0.4) * 
Alcohol consumption N (% >1 drink per day) 
* 
44 (28.4) 5 (2.0) 
Walking per week (mins) 50.3±69.9 47.0±116.5 
Medical Conditions: N (%) 
Hypertension † 46 (30.1) 68 (28.3) 
Obesity †† 31 (20.0) 109 (44.7) *** 
Diabetes ††† 17 (11.0) 42 (17.4) 
Kidney Function Measurements: (Median [Range]) 
Serum Creatinine (mg/dL )  1.01 [0.5-1.8] 0.81 [0.5-2.1]*** 
Urinary Albumin (mg/dL) 0.3 [0.1-47] 0.8 [0.1-128]*** 
Albumin-to-Creatinine Ratio (mg/mmol) 1.3 [0.2-215] 3.8 [0.2-540]*** 
Estimated GFR based on MDRD equation 100.8 [44.1-229.6] 95.4 [27.9-192.6]*** 
 
* Comparison by gender is statistically significant * p<0.05, ** p<0.01, *** p<0.001; 
† Hypertension was defined as a diastolic blood pressure ≥90 mmHg, systolic blood pressure ≥140 
mmHg, or currently taking blood pressure medication. 
†† Diabetes was defined as fasting glucose level ≥126 mg/dl or currently taking diabetes medication. 
††† Obesity was defined as BMI ≥ 30. 
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Table 2.2 Serum Creatinine and Estimated GFR in Aro-Caribbean Family Members by Age 
 
Age (years) Men 
 
Women 
N Creatinine 
(mg/dL) 
MDRD_eGFR N Creatinine 
(mg/dL)  
MDRD_eGFR 
Overall 155 1.04±0.18 106.6±23.9 243 0.86±0.24 96.7±27.4 
    <20 10 0.95±0.09 126.6±14.3 14 0.72±0.10 130.5±24.5 
    20-39 61 0.98±0.13 113.4±22.6 99 0.77±0.13 111.9±21.9 
    40-59 54 1.06±0.14 92.3±14.9 88 0.84±0.15
  
89.5±15.4 
    60-69 17 1.10±0.23 85.51±19.4 24 1.05±0.28 66.4±22.6 
    70+ 13 1.24±0.30 73.0±18.4 18 1.27±0.49 58.3±24.8 
 
* Estimated GFR using MDRD equation: GFR [mL · min-1 ·(1.73 m2) -1] =175 * standardized Serum 
creatinine -1.154 * age -0.203 * 1.212 [if black] * 0.742 [if female] (81). 
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Table 2.3 Comparisons of Age Standardized Decreased eGFR between Afro-Caribbeans and the 
U.S. Population (NHANES III) 
 
 
1. Estimated GFR, calculated by MDRD equation: GFR [mL · min-1 ·(1.73 m2) -1] =175 * standardized 
Serum creatinine -1.154 * age -0.203 * 1.212 [if black] * 0.742 [if female]. Decreased eGFR was defined as 
eGFR < 60 mL/min per 1.73 m2.   
2. The disease prevalence among the African American population was estimated from NHANES III 
2005-2006. Serum creatinine concentration was standardized with the following formula: Standard 
creatinine (mg/dL)=-0.016+0.978*(NHANES 05-06 uncalibrated serum creatinine, mg/dL) (138).    
3. Direct Standardization calculates a weighted average of the region’s age-specific prevalence where the 
weights represent the age-specific sizes of the standard population.  
 
  
 Afro-Caribbean Families African American (NHANES III 2005-2006) 2 
Overall Male Female Overall  Male Female 
N  % N  % N  % N  % N  % N  % 
Age standardized CKD prevalence 3 
Total 395 8.9 --- --- --- --- 1108 6.9 --- --- --- --- 
Age Group 
<20 24 0 10 0 14 0 193 0 102 0 91 0 
20-39 160 0.6 61 0 99 1.0 366 0.8 168 1.2 198 0.5 
40-59 142 2.1 53 0 89 3.4 325 3.0 152 2.6 173 3.3 
60-69 42 23.8 17 11.8 25 32.0 138 18.3 73 20.7 65 15.6 
70+ 31 41.9 13 23.1 18 55.6 86 25.9 49 19.7 37 32.7 
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Table 2.4 Categories of Urinary Albumin-to-Creatinine Ratio by Age Group in Afro-Caribbean 
Families 
 
1 Direct Standardization calculates a weighted average of the region’s age-specific prevalence where the 
weights represent the age-specific sizes of the standard population.  
* Albuminuria was defined by ADA(136) and the National Kidney Foundation(137), as Normal Albumin 
creation ratio (ACR)：<30mg/g; Albuminuria: ACR > 30 mg/g; Microalbuminuria: 30-299 mg/g; 
Macroalbuminuria: ≥300 mg/g. 
  
 Afro-Caribbeans Families  African Americans in NHANES 
2005-2006 
N Micro-
albuminuria 
 N (%) 
Macro- 
albuminuria 
 N (%) 
N Micro- 
albuminuria 
 N (%) 
Macro- 
albuminuria 
 N (%) 
Age Standardized 1 402 9.2% 1260 14.5% 
Men 
    <20 10 0  0 107 3 (2.8) 0 (0) 
    20-39 63  
1 (1.6) 
0 185 5 (2.7) 4 (2.2) 
    40-59 53 2 (3.8) 0 168 12 (7.1) 5 (3.0) 
    60-69 17 1(5.9) 0 95 24 (25.3) 7 (7.4) 
    70+ 13 2 (15.4) 0 62 14 (22.6) 3 (4.8) 
Women 
    <20 14 2 (14.3) 0 98 13 (13.3) 0 (0) 
    20-39 100 5 (5.0) 0 218 22 (10.1) 1 (0.5) 
    40-59 89 6 (6.7) 2 (2.2) 193 26 (13.5) 5 (2.6) 
    60-69 25 4 (16.0) 2 (8.0) 80 13 (16.3) 5 (6.2) 
    70+ 18 6 (33.3) 1 (5.6) 54 10 (18.5) 5 (9.3) 
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Table 2.5 Results of Heribability Estimation for Kidney Function 
 
Trait Covariate Residual 
Heritability 
(hr2) 
Proportion of 
variance due to 
covariates 
Serum Creatinine 1 Age***, sex***, antihypertensive 
medication**, LDL** 
0.28±0.10*** 0.46 
Urinary Albumin 1 Gender***, and Systolic blood 
pressure*  
0.22±0.08** 0.11 
Urinary Albumin 
to creatinine ratio 1 
Gender***, fasting glucose** 
and Systolic blood pressure** 
0.19±0.08** 0.17 
 
1 Measurements of kidney function and BMI were log transformed; 
Significance level: *P<0.05, ** P<0.01, ***P<0.0001, 
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3.1 ABSTRACT 
Background: The public health burden of metabolic syndrome is considerable. Metabolic 
syndrome is defined by a cluster of risk factors, elevated blood pressure, dyslipidemia, central 
obesity, and glucose intolerance, which increase cardiovascular disease and diabetes risk. 
African Americans are at higher risk for hypertension and diabetes, but lower risk for metabolic 
syndrome, compared to U.S. Caucasians. The aim of this study is to characterize the metabolic 
syndrome in a sample of Caribbean African-origin families and estimate the heritability of 
metabolic risk factors to better understand the underlying pathophysiological mechanisms. 
Method: Components of metabolic syndrome: lipids, central obesity, fasting glucose and insulin 
and blood pressure were measured among 401 individuals aged 18 to 103 years (mean age: 42.4 
± 16.9 years) from seven multigenerational African Caribbean pedigrees (average family size: 
50; range: 19 to 96; nearly 3500 relative pairs. Metabolic syndrome was defined according to the 
World Health Organization (WHO), International Diabetes Federation (IDF), and National 
Cholesterol Education Program Expert Panel and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment panel III) (NCEP/ATP III) definitions. Heritability (h2) was estimated with 
maximum likelihood methods. To obtain the structures underlying metabolic syndrome, factor 
analysis was performed in SAS (9.2). Results: Among these Afro-Caribbeans, 9.4% (11.3% 
women and 5.4% men), 18.7% (23.9% women and 10.7% men), and 25.3% (30% women and 
18% men)  had metabolic syndrome using WHO criterion, NCEP/ATP III and IDF definition, 
respectively. The heritability of each component ranged from 21% for large waist circumference 
to 46% for HDL-cholesterol (P<0.05).  Factor analysis of the components produced two major 
factors: factor 1, comprised of lipids, central obesity and fasting glucose and insulin, was 29% 
heritable (p=0.0001), and factor 2, comprised of systolic and diastolic blood pressure, was 20% 
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heritable (p=0.002). Conclusion: Moderate and significant heritability of metabolic syndrome 
and each of its components was estimated among these African Caribbean families. Future 
studies are needed to identify underlying susceptibility genes for specific components of 
metabolic syndrome.  
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3.2 INTRODUCTION 
Metabolic syndrome (MetSyn) is a clustering of risk factors, central obesity, 
hypertension, dyslipidemia, hyperinsulinemia and diabetes, which increase the risk of developing 
cardiovascular disease and diabetes. There are many published versions of the definition for 
MetSyn, with varying combinations of risk factors, as proposed by the World Health 
Organization (WHO), National Cholesterol Education Program Adult Treatment Panel III 
(NCEP/ATP III) , European Group for the Study of Insulin Resistance (EGIR), American 
Association of Clinical Endocrinologists (AACE), and the International Diabetes Federation 
(IDF)(34-39). The prevalence of metabolic syndrome is high among U.S. adults and increasing 
in both men and women. The age-adjusted prevalence for MetSyn (defined by ATP III) was 
24.1% in NHANES III (1988-1994) (40), 27% in NHANES III 1999-2000(3) and 34% in 
NHANES 2003-2006 (154). High blood pressure, waist circumference and hypertriglyceridemia 
accounted for much of the increased prevalence rate (3). The prevalence of metabolic syndrome 
varies among ethnic groups. Mexican Americans have the highest age-adjusted prevalence of the 
metabolic syndrome (31.9%) compared to Caucasians (23.8%) and African Americans (21.6%) 
(40). MetSyn is the focus of intense research due to its association with adverse complications 
such as cardiovascular disease (4), stroke (155) and diabetes(156).  
The lack of consensus on definition leads to the debates on whether there is genetic basis 
for MetSyn. Indeed, growing evidence from families and twin studies has yielded significant 
heritability estimations for the individual components of the metabolic syndrome such as obesity, 
insulin resistance, dyslipidemia and hypertension (157-160). Since metabolic syndrome is 
characterized by constellation of highly intercorrelated quantitative phenotypes, factor analysis 
and principle component approach have been used to simplify the syndrome and have potentially 
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provided new insights into the pathophysiology of the disease (161-164). The Northern 
Manhattan Family study investigated Caribbean-Hispanic families and demonstrated 24% 
heritability for metabolic syndrome itself, individual five components from 16 to 60% and two 
independent factors (44% for lipids/glucose/obesity, and 20% for blood pressure)(11). 
While cardiovascular disease (CVD) rates specific to the Caribbean Africans residing in 
the island of Tobago are not available, the Trinidad & Tobago government has classified CVD as 
one of the five leading causes for death in all age groups in the combined population of the two 
islands. The Tobago population is predominantly of West African origin, with a  low admixture 
rate (6% non-African) (109). With the advancing westernization of lifestyle, the Tobago 
population is exposed to high risk for obesity, hyperglycemia and hypertension, to categorize as 
metabolic syndrome. A previous study in Trinidad and in Tobago found that a higher prevalence 
rate of MetSyn were present among diabetic patients in both islands (165). However, no accurate 
estimation of metabolic syndrome among Afro-Caribbeans has been conducted. Our study will 
be the first to evaluate the heritability of metabolic syndrome related phenotypes among the 
Tobago population.  
The aim of this study is to characterize the metabolic syndrome in a sample of Caribbean 
African-origin families, estimate the heritability of metabolic syndrome related components. In 
order to understand the genetic architecture of metabolic syndrome, factor analysis was 
performed to examine the existing pattern of correlations between metabolic measures and 
explain the underlying genetic background.  
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3.3 METHODS 
3.3.1 Study Population 
We began the Tobago Family Health Study on the island of Tobago to assess heritability 
and better understand the genetic and environmental factors which contribute to the metabolic 
phenotypes including subclinical cardiovascular disease, diabetes, obesity and chronic kidney 
disease. To be eligible, a proband must have been Afro-Caribbean, have had a spouse who was 
willing to participate in the study and have at least six living offspring and/or siblings aged 18+ 
years who were residing in Tobago.  Recruited without regard to their health status, to date, 401 
individuals have been enrolled into the study; the mean age was 43 years, ranging from 18 to 103 
years. They belong to seven multigenerational families (mean family size 51 individuals) of 
Western African ancestry with the following relationship: 361 parent-offspring, 495 full siblings, 
101 grandparent-grandchildren, 1,137 avuncular, 61 half-sibs, and 1,380 cousins (3,535 relative 
pairs). The population from Tobago is predominantly African origin with low 6% admixture, 
which has been confirmed from previous study using molecular markers(109). Metabolic traits 
measurements are available among 401 of 471 participants in this community-based sample of 
families. Written informed consent was obtained from each participant using a protocol and 
consent forms approved by the Institutional Review Boards of the University of Pittsburgh and 
the Tobago Division of Health and Social Services.  
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3.3.2 Data Collection 
Height was recorded to the nearest 0.1 cm using a wall-mounted stadiometer. Weight was 
measured to the nearest 0.1kg without shoes on a balance-beam scale. Waist circumference was 
measured at the narrowest point of the waist using an inelastic fiberglass tape. Information on 
demographic characteristics (race/ethnicity), medical history, and lifestyle habits (smoking 
status, alcohol intake, oral contraceptive use, physical activity [minutes per week]) was obtained 
by questionnaire and interview by trained and certified clinical staff. Participants were asked to 
bring prescription and nonprescription medications to the clinic for verification. Race/ethnicity 
was self-declared. Detailed information on the ethnic origin of their parents and grandparents 
was provided by participants. Individuals were assigned to an ethnic group if they reported that 
all four grandparents belonged to that group. Blood pressure was measured three times using an 
automated blood pressure machine (Omron model HEM-705CP, Illinois); systolic blood pressure 
and diastolic blood pressure were calculated based on the average of the second and third 
measurements. 
Diabetes was defined as a fasting glucose level greater or equal to 126mg/dL or currently 
taking anti diabetes medication. Hypertension was defined as diastolic blood pressure ≥90 
mmHg, or systolic blood pressure ≥140 mmHg, or currently taking blood pressure medication. 
3.3.3 Blood Sample Collection and Lab Measurements 
A blood sample was obtained by venipuncture in the morning after 12 hours fasting. Whole 
blood was drawn into sterile red top (serum) tubes, which were left to clot at the room 
temperature for 20 minutes before centrifugation. Then serum was aliquotted into 1 mL 
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cryovials. The aliquots of serum samples were frozen, and shipped on dry ice to the University of 
Pittsburgh where they were stored in a -80 ºC freezer.   
Metabolic traits (serum glucose, insulin, triglycerides, HDL, microalbumin) were 
measured in the Heinz Nutrition Laboratory, University of Pittsburgh, using standard lab 
analytical procedures. The accuracy and precision of each technique was verified. Accuracy was 
estimated by comparing values obtained for the reference controls with their stated values. 
Precision was evaluated as the coefficient of variation both intra-assay and inter-assay. Briefly, 
serum glucose was quantitatively determined by an enzymic determination read at 340/380 
nm(166). The coefficient of variation between runs was 1.8%. Insulin was measured using an 
RIA procedure developed by Linco Research, Inc. The coefficient of variation between runs was 
10%. Triglycerides were determined enzymatically using reagents from Clinical 
Diagnostics(167).  Coefficient of variation between runs was 1.7%. HDL cholesterol was 
determined after selective precipitation by heparin/manganese chloride and removal by 
centrifugation of very low density (VLDL) and low density lipoprotein (LDL)(168). The 
coefficient of variation between runs was 1.3%. Microalbumin in urine was measured using a 
turbidimetric procedure on the Olympus AU400 using reagents provided by Olympus America, 
Inc. The intra- and inter-assay coefficients of variation were below 2.5% and 5.1%, respectively. 
3.3.4 Metabolic Syndrome Definition 
World Health Organism (WHO) published the first official guidelines, followed by the 
definition from National Cholesterol Education Program Expert Panel and Treatment of High 
Blood Cholesterol in Adults (NCEP / ATP III) and the International Diabetes Federation (IDF). 
NECP/ATP III has been widely used in large epidemiological studies, such as the Third National 
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Health and Nutrition Examination Survey (NHANES III) in the U.S. Table 1 compares the 
diagnostic criteria for metabolic syndrome according to the three definitions, which differ in 
combinations of risk factors. According to WHO consultation group (169), 1) Insulin resistance 
was viewed as a required component for diagnosis; 2) A higher blood pressure cut point 
(140/90mmHg) was required, compared with the later definitions (ATP III and IDF define 
hypertension as blood pressure greater than 130/85 mmHg); 3) Increased waist: hip ratio (or 
BMI) rather than waist circumference, and microalbuminuria were listed as additional criteria in 
WHO definition. The requirement of objective evidence of insulin resistance should increase the 
power of WHO definition to predict diabetes compared with the later definitions. In terms of 
waist circumference, the ATP III definition introduces a uniform cut point of increased waist 
circumference, which fails to capture the elevated risk in Asian population at relatively lower 
levels of abdominal obesity. In contrast, the International Diabetes Federation developed ethnic 
specific definitions. The Asian population has a lower cut point for waist (men: 90cm, women 
80cm) compared to Europids (men: 94cm, women 80cm). However, ethnic-specific definition 
has not been developed for other ethnic groups, e.g. population of African descent; thus, in U.S. 
clinics, the value used in ATP III definition (men: >102, women >88) is still used for clinical 
purposes.   
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Table 3.1 Diagnostic Criteria of Metabolic Syndrome Definitions: WHO, ATP III and IDF 
 
IDF: ethnicity specific cut point of waist circumference is used, Asian population is considered having a 
lower cut point (men >90, women >80 cm), however in the U.S. the same value as ATP III is used in 
clinic settings. 
 
  
 WHO (insulin resistance plus 
two of the following) (169) 
ATP III (three of the 
following) (38) 
IDF (central obesity plus 
two of the following) (35, 
45) 
Abdominal /central obesity 
 Waist to hip ratio: Waist Circumference: Waist Circumference: using 
ethnicity specific cut point* 
Men >0.90 >102 cm (40in) >94cm 
Women >0.85 >88cm (33in) 80 cm 
Hypertriglyceridemia 
 ≥150 mg/dL (1.7 mmol/L) ≥150 mg/dL  ≥150 mg/dL  
Low HDL cholesterol 
Men  <35 mg/dL (0.9 mmol/L) <40 mg/dL <40 mg/dL 
Women <39 mg/dL (1.0mmol/L) <50 mg/dL <50mg/dL 
High Blood Pressure 
 ≥140/90 mmHg or use of 
antihypertensive medication 
≥130/85 mmHg or  anti-
hypertensive medication 
usage 
≥130/85 mmHg or use of 
antihypertensive 
medication 
High fasting Glucose 
 Type 2 diabetes, impaired 
fasting glucose (FBG  ≥ 
6.1mmol/l), impaired glucose 
tolerance (2hPPG ≥ 7.8 
mmol/l) 
Impaired fasting glucose 
(FBG ≥ 6.1 mmol/L)  or 
drug treatment for high 
glucose 
FBG 5.6mmol/L or 
previous diagnosis of 
impaired glucose tolerance 
or diabetes 
Others  Microalbuminuria 
(albumin:creatinine ratio ≥30 
mg/g) 
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3.3.5 Statistical Analysis 
Initially, the distributions of all metabolic traits were assessed for non-normality and data was 
transformed before analysis to reduce non normality. Outliers (defined as ±4 SD) were removed. 
No more than four values were removed for a single variable.  
All potential covariates for each trait were screened using linear/logistic regression 
analysis, ignoring the non-independence of subjects using SAS (9.2). The significance level was 
set as 0.10 at this screening stage. Subsequently, we evaluated each of the potential significant 
covariates using a variance component framework which takes into account of the correlations 
among family members. To estimate the heritability among metabolic syndrome and its 
components, we analyzed each component as dichotomized trait as defined in the ATP III. We 
also estimate heritability for quantitative data of each continuous component of this syndrome 
with adjustment for covariates and medications to reduce the misclassification of phenotypes. 
These analyses were performed using the program SOLAR (Sequential Oligogenic Linkage 
Analysis Routines, Copyright © 1995-2003, Version 2.1.4; Southwest Foundation for 
Biomedical Research, San Antonio, TXT). With this approach, the maximum-likelihood 
estimation is applied, incorporating significant covariate effects, additive genetic effects and 
residual error. The additive genetic effects and residual error are assumed to be normally 
distributed and to be mutually independent. Heritability is calculated as the proportion of 
phenotypic variance explained by additive genetic effects after accounting for covariates.  
For factor analysis, the normally distributed, or otherwise, log transformed continuous 
traits were first adjusted for age, sex, age2, and age2 by sex, by multiple regression and the 
standardized residual were obtained. Blood pressures were adjusted for use of antihypertensive 
medication by adding 15mm Hg and 10mm Hg to SBP and DBP respectively (170). Image 
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factoring was used to extract the factors. The promax rotation, as a common orthogonal rotation 
option, was used to make the output more understandable (171). Factor numbers were 
determined by Eigen value-one criterion and the scree test, which is a plot of variance associated 
with each factor. A distinct break presents between the steep slope of the large factors and 
gradually trails off. It is also suggested by Meigs, JB et al that the number of factors equals or is 
less than the number of original variables divided by three(172). Items with loading > 0.40 were 
considered as large effect and entered the factor (173). Weighted factor scores were used, which 
was determined by the sum of the values of the phenotypes multiplied by standardized scoring 
coefficients for that factor. SAS (9.2) was used to perform factor analysis.  
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3.4 RESULTS 
The Tobago Family Heath Study consisted of 401 individuals from seven 
multigenerational families who had enrolled to date with available metabolic traits 
measurements. The average family size was 50, ranging from 19 to 96. The mean age was 43.3 
years (SD=16.9), similar among men and women, with a range from 18 to 103 years. Men 
accounted for 39% of the study subjects. Characteristics of metabolic syndrome and its 
components are shown in Table 3.2. Compared to women, Tobago men had higher systolic 
(p<0.0001) and diastolic (p=0.03) blood pressure and percentage of hypertension (p=0.05). 
Though Tobago women had higher fasting glucose level and the rate of diabetes, such trends did 
not reach statistical significance. Mean HDL-cholesterol level in Tobago was 40.0 ± 12.4 mg/dL 
(men: 39.4 mg/dL, women: 40.9 mg/dL). More than half of the participants had low HDL 
cholesterol (67.4%: men 50% vs. women 78.5%). According to the WHO definition, 9.4% Afro-
Caribbean (11.3% women and 5.4% men) are suffering metabolic syndrome, which is the lowest 
proportion compared to the other definitions 18.7% (23.9% women and 10.7% men) by ATP III, 
and 25.3% (30% women and 18% men) by IDF (Table 3.2).  
Table 3.3 shows the heritability estimation. When the components were treated as 
continuous variables, the residual heritability varied from 12% for fasting glucose to 46% for 
HDL-cholesterol after adjustment for age, sex and appropriate medication. When the metabolic 
traits were treated as discrete traits according to ATPIII cut points, the estimated heritability 
varied from 21% for large waist circumference to 72% for high fasting glucose level.  
The correlations between metabolic traits were then examined adjusting for age and sex. 
The partial correlation coefficients were shown in Table 3.4. All the components were 
significantly intercorrelated except for blood pressure and lipids profile. As expected, the 
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correlation between systolic blood pressure and diastolic blood pressure is very high, (r=0.75, 
p<0.001). Total cholesterol is also highly related to triglycerides (r=0.41, p<0.001). The factors 
and patterns of factor loading are shown in Table 3.5. Two significant factors were extracted 
from eight metabolic traits: total cholesterol, HDL, triglycerides, waist, fasting glucose, insulin 
and systolic and diastolic blood pressure. The first factor explained 55.8% of variance, 
comprised of lipids, central obesity and fasting glucose and insulin. The second factor accounted 
for 26.8% of variance, and was dominated by systolic and diastolic blood pressure. The 
heritability estimations for these two factors were both significant, 0.29 (p<0.0001) and 0.20 
(p=0.002) respectively. 
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3.5 DISCUSSION  
In this study, we found a significant heritability of metabolic syndrome related traits 
among Afro-Caribbean families. The estimated heritability ranged from 12% to 46% for fasting 
glucose to HDL cholesterol. To our knowledge, this is the first report of heritability of metabolic 
syndrome related traits among Afro-Caribbeans. Our results confirmed that genetic contributors 
play a role in the familial aggregation of metabolic syndrome. Using factor analyses approach, 
the heritability of factor one (comprised by central obesity, glucose and lipids) was 29% 
heritable (P<0.0001) and factor two (comprised by blood pressure) was 20% heritable. Although 
the significant heritability estimated from both factor analysis and metabolic traits are not 
directly comparable because they comprise different traits, these results illustrated that there is an 
underlying genetic contributions to the metabolic syndrome.  
Rather than a clinical disease, metabolic syndrome by definition is a cluster of the 
intercorrelated risk factors. Variation in prevalence of metabolic syndrome across population is 
influenced by the use of different definitions, as well as by differences in distributions of 
individual metabolic traits across population. Ethnic differences in metabolic syndrome 
prevalence have been reported. As documented in NHANES survey data, African American men 
had a nearly 50% lower rate (13.9% vs. 20.8%, P=0.006); African women had similar rate as 
Caucasians (20.9% vs. 22.9%, P=0.10) using the ATP III  definition (174). Different patterns of 
metabolic risk factor prevalence do exist across populations. For instance, low HDL cholesterol 
and central obesity are the most two important contributors among Caucasians, while, 
hypertension and central obesity are  the top risk factors among African Americans, and central 
obesity and hyperglyceridemia are the major contributors for Mexican Americans (154). By 
gender, white and Mexican American men had the highest age adjusted prevalence rate of central 
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obesity, hypertriglycerides and low HDL cholesterol; African American men had the highest age 
adjusted prevalence of high blood pressure and Mexican American men had the highest age 
adjusted prevalence of hyperglydemia. Among women, Mexican Americans and African 
Americans had the highest age adjusted prevalence of abdominal obesity, African American 
women had the highest age adjusted blood pressure and Mexican American women had the 
highest age adjusted prevalence of hypertriglycerdemia, low HDL cholesterol and 
hyperglydemia (154). Furthermore, all these metabolic traits are correlated with each other. The 
degree of the correlation between these risk factors was also differentiating across ethnic groups.  
For example, the increased waist circumference significantly correlated with the increased risk 
for diabetes and hypertriglyceridemia among Hispanics compared to whites (Hispanic men 0.12 
vs. white men 0.10 and 0.12 vs. 0.08 for women respectively); but it was closely related to 
hypertension among black population (175). Thus, in addition to the differences across 
definitions, no matter which definition is used, metabolic syndrome is a very heterogeneous 
phenotype across ethnic groups rather than a well defined clinical presentation. By saying that, 
both environmental and genetic factors are playing the role. Thus, comparison of the estimated of 
heritability of metabolic traits as a single phenotype, i.e. metabolic syndrome, across population 
has little meaning.   
According to NHANES, African Americans have a lower prevalence of metabolic 
syndrome than whites. Our study confirmed that the low rate of metabolic syndrome also exist 
among African ancestry from Caribbean island. The lower rate in blacks is partly ascribed to the 
unique features among blacks, namely the lower serum triglyceride level, higher HDL 
cholesterol when compared to whites. Despite these favorite lipids and lipoprotein profile, 
African population has high prevalence of central obesity and hypertension, resulting in higher 
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cardiovascular mortality and mobility. Although the reasons are uncertain and appear to be 
multifactorial, blacks have higher serum insulin and insulin resistance than whites (176).  
Recently, Haffner et al showed that in addition to lower serum triglycerides, African Americans 
have larger LDL-particle size, which are more elastic and less atherogenic than whites (177). The 
paradox of favorable lipid profile and conversely the unfavorable hypertension in blacks calls 
into the question whether the current criteria of metabolic syndrome is valid among blacks. In 
our study, we found that African Caribbean population has low triglyceride level, but unlike 
African American, they possess the low HDL cholesterol, especially among Tobago women. The 
underlying reason is unclear and future studies are needed to confirm among other African 
ethnicity groups. In addition, we reported that Tobago women have much higher risk of 
metabolic syndrome compared to Tobago men. This could be attributed to psychological 
difference including hormone level or lifestyle factors such as eating habits, physical activity.  
Moreover, the heritability estimation represents the proportion of total phenotypic 
variance which is attributable to additive genetic variations; the heritability of the same trait will 
differ between populations that differ in the distribution of life style risk factors for that trait. 
Reported from previous studies, the estimates of heritability ranged from 15% to 40% in blood 
pressure, 25-60% in BMI, 40-60% in HDL cholesterol and 25-30% in fasting glucose across 
different populations (178). Among families from North European origin, after adjusting for age 
sex and body mass index, the heritability estimates for fasting glucose, triglycerides and HDL 
cholesterol were 20%, 20% and 43% respectively(179). In Mexican families, estimated 
heritabilities are fasting glucose (18%) triglyceride (40%) and HDL-cholesterol (49%).  In our 
study, the observed heritability is modestly high among these African Caribbean families: fasting 
glucose (36%), HDL-cholesterol (46%), triglyceride (18%), systolic BP (25%), diastolic BP 
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(31%) after adjusting for age and gender. These estimations are in the range of commonly 
reported heritability estimation from other populations. Participants who were currently taking 
medication for hypertension and diabetes were excluded from this analysis. Even though 
heritability estimation of individual components varied among different populations, the 
significant finding in our study, consistent with previous research, indicated that there are 
underlying genetic influences on all of the components. Accumulated evidence suggests that 
metabolic syndrome most likely results from the interplay between several genes and an affluent 
environment(180). Lin et al confirmed that genetic factors contributed to the familial aggregation 
of metabolic syndrome among Caribbean-Hispanic families; they found that HDL cholesterol 
had highest estimation of 60% heritability, while systolic blood pressure had the lowest one of 
16% (11).  
In order to better understand the structures of clustering of the metabolic traits, factor 
analysis or principle component analysis has emerged as a useful method to understand patterns 
underlying metabolic risk factors. As reviewed by Teran-Garcia et al, factor analysis or principle 
component analysis have been used by many investigators to demonstrate that common genes 
exert pleiotropic effects on these metabolic traits based on the assumption of the presence of 
common genetic and/or environmental factors underlying these components(180). In fact, as an 
argument against ‘common ground’ or a ‘yes/no’ metabolic syndrome, previous studies have 
broken the related metabolic traits into two(11, 163, 164), three (161, 162, 181, 182)or four (183-
185) factors. In general, central obesity related traits, together with lipids, insulin and fasting 
glucose, fall into one factor distinguished from the measures related to blood pressure, which 
form a separate factor. We were able to produce two factors from seven metabolic syndrome 
related traits, with the similar patterns indicated by previous studies. The number of retrieved 
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factors obeyed the rule of equaling or less than the number of included traits divided by three. 
The failure of blood pressures to load with several other components on one factor was 
consistently reported by other studies. We found that factor 1 comprising of only lipids, glucose 
and central obesity explained majority of the variance (55.8%), and had heritability of 29% 
(p=0.0001), which was comparable to the heritability estimation among Japanese-American 
population(162). Another factor was found to be comprised of blood pressure, which explained 
for 26.8% of total variance and had 20% heritability (p=0.001). Very few studies have presented 
results from factor analysis among African Americans. Evidence from Miami Community Health 
Study showed that the identical factor patterns appear in black and white populations, but the 
small sample size (50 participants including 23 African Americans) limited their power to 
address the issue appropriately (186). Two principle components were used in the HERITAGE 
Family Study, which explained 55% of total variance in metabolic traits among 456 white and 
217 black participants. Promising evidence for linkage has been found for both blacks and 
whites, suggesting the genetic basis for metabolic syndrome. However, the fact that quantitive 
linkage patterns are different from blacks to whites underlines the existence of different risk 
factor distribution across various ethnic populations. (164) Future studies are needed to identify 
the risk factor patterns of metabolic syndrome among African origin populations.    
Our study was the first study of metabolic conducted syndrome conducted among non 
patient population in the island of Tobago. We have several strengths and limitations. We 
recruited participants from seven multigenerational families, with extended family members, 
which provide better power to detect genetic signals than nuclear families or sib-pair data. Such 
family structure will give more accuracy in heritability estimation. The relationship among 
individuals has been validated by genotyping data, so we minimized the possibility of inaccurate 
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reports of biological kinship. However, our study does have limitations. First, the sample size 
was relatively small; about 400 individuals have complete measurements on all metabolic trait 
measurements. Secondly, even though we recruited people without regarding to their health 
status, these participants are ambulatory. It is possible that we underestimated the disease burden 
in the general Afro-Caribbean population.  
In summary, we report a moderate and significant heritability of metabolic syndrome and 
its components estimated among these African Caribbean families. Factor analysis illustrated 
two clusters of related risk factors with significant heritability. Further linkage studies or 
association studies are strongly needed to identify specific loci contributing to the susceptibility 
of metabolic syndrome.    
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Table 3.2 Characteristics of the Study Participants 
 
 
a Hypertension is defined as blood pressure ≥ 130/85 mmHg or currently taking anti hypertensive 
medication 
b Diabetes is defined as fasting glucose ≥ 126 mg/dL or currently taking anti diabetic medication 
c High triglycerides is defined as TG ≥ 150 mg/dL 
d Low HDL cholesterol is defined as HDL <40 mg/dL (men), <50 mg/dL (women) 
e High waist circumference is defined as >102cm (men), > 88 cm (women) 
f WHO definition is impaired glucose tolerance or diabetes or insulin resistance and 2 of the other factors, 
including type 2 diabetes, BMI > 30 kg/m2, TG > 150 mg/dL, HDL < 35 mg/dL (men) <39 mg/dL 
(women), Blood pressure ≥ 140/90 mmHg and microalbuminuria 
g ATP definition is three or more of the following factors: impaired fasting glucose, increased waist 
circumference >102 (men) >88 (women), HDL <40 (men) <50 (women) and Blood pressure ≥ 130/85 
mmHg 
h IDF definition is central obesity and 2 other factors: fasting glucose ≥ 110mg/dL, waist circumference 
≥94(European men) ≥80 (European women) ≥ 90 (Asian men) ≥80 (Asian women), HDL <40 (men) <50 
(women), BP ≥130 / 85 mmHg. 
 All, n=401 Women, n=245 Men, n=156 P  value 
Age (years) 42.4±16.9 42.6±17.3 42.1±16.9 0.75 
Waist circumference (cm) 89.9±15.4 89.6±17.2 90.3±12.4 0.71 
Height (cm) 170.7±8.6 166.5±6.4 177.4±7.1 <0.0001 
Weight (kg) 82.3±19.1 80.8±19.7 84.5±17.8 0.08 
Body mass Index (kg/m2) 28.2±6.5 29.2±7.1 26.8±5.1 <0.0001 
Fasting glucose (mg/dL) 87.8±28.3 89.3±31.7 85.5±21.9 0.07 
Triglycerides (mg/dL) 88.7±46.4 85.5±43.0 93.6±51.0 0.06 
LDL-cholesterol (mg/dL) 131.3±40.1 134.0±41.7 127.2±37.4 0.08 
HDL-cholesterol (mg/dL) 40.0±12.4 39.4±12.7 40.9±11.7 0.16 
Systolic blood pressure (mmHg) 122.9±24.4 119±25.7 128.8±21.0 <0.0001 
Diastolic blood pressure (mmHg) 76.3±12.9 75.1±13.1 78.1±12.4 0.03 
Insulin (mIU/ml) 15.9±9.9 17.2±10.9 13.9±7.7 0.001 
Hypertension (%) a 35.6 31.7 41.8 0.08 
Diabetes (%) b 14.9 17.4 11.0 0.11 
High triglycerides (%) c 7.7 7.0 9.0 0.46 
Low HDL cholesterol (%) d 67.4 78.5 50.0 <0.0001 
High waist circumference (%) e 37.6 52.1 15.4 <0.0001 
Metabolic Syndrome (%)     
    WHO definition f 9.4 11.3 5.4 0.05 
    ATP definition g 18.7 23.9 10.7 0.001 
    IDF definition h 25.3 30 18 0.008 
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Table 3.3 Heritability Estimation for Metabolic Syndrome (ATP III Definition) related Components Treated as Both Continuous and 
Discrete Traits 
 H2 (SE) P-value Variance explained by covariates f 
Waist    
    cm a 0.19 (0.11) 0.02 0.08 
    Women >89, men >102 b 0.22 (0.20) 0.10 0.15 
Fasting Glucose    
    mmol/L a c d 0.36 (0.14) 0.004 0.05 
    ≥6.1 b d 0.88 (0.47) 0.03 0.10 
Triglycerides    
    mmol/L a c 0.18 (0.10) 0.008 0.14 
    ≥1.7 b 0.21 (0.25) 0.16 0.03 
HDL cholesterol    
    mmol/L a 0.46 (0.11) <0.001 --- 
    Women <1.3, men <1.04 b 0.36 (0.19) 0.002 0.07 
Blood Pressure    
    Systolic, a c e 0.25 (0.09) 0.0002 0.36 
    Diastolic, a c e  0.31 (0.10) <0.0001 0.27 
    Systolic≥130 or diastolic ≥85 
or anti hypertensive medication b 
0.33 (0.20) 0.02 0.27 
 
*<0.05, ** <0.0001 
a – treated as continuous traits 
b – treated as discrete traits 
c – log transformation 
d – participants with anti- diabetic medication were excluded from analysis 
e – participants with anti-hypertensive medication were excluded from analysis 
f – Proportion of variation explained by covariates of age and gender   
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Table 3.4 Partial Correlation Coefficient between Variables Used in Factor analysis (Controlling for Age and Gender) 
 
 Waist Triglycerides Total cholesterol
HDL 
Cholesterol
LDL 
Cholesterol
Fasting 
Glucose
Fasting 
Insulin 
Systolic 
BP 
Diastolic 
BP 
Waist  1.00         
Triglycerides  a 0.28** 1.00        
Total Cholesterol a 0.13* 0.41** 1.00       
HDL Cholesterol  -0.14* -0.16* -0.13* 1.00      
LDL Cholesterol 0.11* 0.25** 0.92** -0.43** 1.00     
Fasting Glucose ac 0.22** 0.17** 0.14* -0.17* 0.17* 1.00    
Fasting Insulin ac 0.46** 0.34** 0.05 -0.12* 0.02 0.31** 1.00   
Systolic BP a b 0.13* 0.08 0.01 -0.05 0.03 0.19* 0.11* 1.00  
Diastolic BP a b 0.12* 0.09 0.1 -0.03 0.09 0.16* 0.05 0.75** 1.00 
 
*P <0.05; **p<0.0001 
a log transformation to achieve normality 
b Adjusted for use of antihypertensive medication by adding 15mm Hg and 10mm Hg to SBP and DBP respectively  
c Exclude participants with anti diabetic medication 
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Table 3.5 Factor  Analysis of Metabolic Syndrome Components, Variance Components and Heritability Estimation 
 
Factor 1 
 (lipids/central 
obesity/glucose) 
Factor 2   
(blood pressure) 
Total Cholesterol a 0.47 0.02 
HDL cholesterol a  -0.35 -0.06 
Triglycerides  a 0.76 0.03 
Fasting Glucose a 0.41 0.12 
Fasting Insulin a 0.71 -0.0002 
Waist a 0.67 0.07 
Systolic BP a b 0.08 0.95 
Diastolic BP a b 0.10 0.94 
Percent of variance (%) 55.8 26.8 
Heritability 0.29  (p = 0.0001) 0.20 (p = 0.002) 
 
a adjusted for age, age2, age2*sex and sex 
b Adjusted for use of antihypertensive medication by adding 15mm Hg and 10mm Hg to SBP and DBP respectively  
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4.1 ABSTRACT 
Objectives: To test the hypothesis that decreased renal function may be related to subclinical 
cardiovascular disease (CVD) in this community-based sample of African ancestry families. 
Design and Methods: 402 participants aged 18 to 103 years (male: 42.1 ± 16.9 (SD) years, 
female:  42.6 ± 17.3 (SD) years), from 7 large, multi-generation pedigrees (average family size: 
50; range: 19 to 96; nearly 3500 relative pairs) were included in this study. Subclinical 
cardiovascular disease was examined by ankle brachial index (ABI), pulse wave velocity (PWV) 
and carotid intima-media thickness (IMT). Serum cystatin C and creatinine were measured using 
standard protocols. Estimated GFR was calculated using Modification of Diet in Renal Disease 
Study (MDRD) formula for standardized serum creatinine. Multivariate regression analysis was 
used to evaluate the association between subclinical CVD and renal function measures adjusted 
for conventional CVD risk factors. The variance component approach was implemented in 
SOLAR to assess the associations, incorporating the effects of the relatedness of family 
members. Results: The mean ± SD cystatin C was 0.62 ±0.19 mg/L, serum creatinine, 0.93 ± 
0.23 mg/dL, and microalbumin, 2.6 ±9.3 mg/dL. Cystatin C was significantly related to ABI 
(P=0.02) and PWV (P=0.04), but not to IMT. Serum creatinine, microalbuminuria and eGFR 
were not significantly associated with these markers of subclinical cardiovascular disease. The 
heritability of serum cystatin C was 0.32 ± 0.1 (P<0.0001), after adjusting for age, gender, 
hypertension, triglyceride and insulin level. Conclusion: Our data suggest that cystatin C is 
significantly heritable (h2=0.32, p<0.0001) among these Afro-Caribbean families. In addition, we 
detected a significant association between peripheral arterial disease and arterial stiffness with 
cystatin C, but not with the other renal function measurements among these Afro-Caribbean 
families.   
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4.2 INTRODUCTION 
Cardiovascular disease (CVD) is the leading cause of death in United States; nearly 2600 
Americans die as a result of CVD every day. The pathological process starts many years before 
the life-threatening events occur. Studies show strong evidence that the incidence of CVD and 
mortality are substantially increased for people with subclinical cardiovascular disease compared 
to those without subclinical disease (1, 187-189). With the advances in technology, identifying 
and quantifying subclinical cardiovascular disease is noninvasive and sensitive, and these 
methods are being translated into clinic practice (190). B-mode ultrasound examination of the 
carotid arteries is the most commonly used measurement to monitor atherosclerosis as assessed 
by intima-media wall thickness (IMT). Lower-extremity peripheral arterial disease (PAD) can be 
detected noninvasively indicated by the ankle-brachial index (ABI), a ratio of systolic blood 
pressures in the lower and upper extremities. Pulse wave velocity (PWV) is an index of arterial 
stiffness that is now easily quantitated using a simple device developed for measurement of the 
brachial-ankle PWV.  baPWV is a useful predictor of coronary artery diseases(191).   
Cystatin C is an alternative marker of kidney function. Unlike the more commonly used 
marker, serum creatinine, which is a by-product of muscle cells and affected by many factors 
other than kidney disease, cystatin C is produced by all nucleated cells and is excreted into the 
bloodstream at a constant level without impact of age, gender, race and muscle mass (78, 79). 
Numerous studies found that cystatin C levels were more accurate to predict glomerular filtration 
rate (GFR) in various clinical presentations, especially in mild to moderate kidney disease 
patients (eGFR between the range of 60 to 90 [mL · min-1 · (1.73 m2) -1]) (82, 86, 192). Cystatin 
C was also found to be a stronger predictor of subclinical coronary atherosclerosis (193), 
peripheral arterial disease(194), all-cause mortality, cardiovascular mobility and heart failure 
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(195, 196) independent of its relationship to renal function. The underlying mechanisms 
accounting for such associations are not clear but may involve insulin resistance and 
inflammation (175, 197).  
The impact of ethnicity and race on subclinical CVD is substantial. African Americans 
have significantly lower amounts of coronary artery and carotid artery calcified plaque relative to 
whites despite having increased carotid IMT and blood pressure(2). The Tobago population is 
approximately 94% of West African origin (109) and is at high risk of hypertension, diabetes, 
cardiovascular disease and impaired kidney function. No previous study has comprehensively 
studied the association of the renal function, assessed by both serum creatinine and cystatin C, 
with subclinical cardiovascular disease measurements in a population of African descent. The 
purpose of this study is to assess the association between renal function markers and subclinical 
coronary atherosclerosis, arterial stiffness and peripheral arterial disease in this African 
Caribbean population.  
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4.3 METHODS 
4.3.1 Subjects and Methods 
This study was conducted in 402 individuals aged 18-103 years (mean age 42 years) 
belonging to seven, multi-generation Afro-Caribbean families (mean family size 51 individuals) 
on the Tobago Island. To be eligible, a proband must have been Afro-Caribbean, have had a 
spouse who was willing to participate in the study and have at least six living offspring and/or 
siblings aged 18+ years who were residing in Tobago.  Among these individuals, we have the 
3535 relative pairs, including 361 parent-offspring, 495 full sibling, 101 grandparent-
grandchildren, 1137 avuncular, 61 half sibs and 1380 cousins. Complete data for the current 
analysis was available in 402 individuals. Written informed consent was obtained from each 
participant, using forms and procedures approved by the Tobago Division of Health and Social 
Services and the University of Pittsburgh, Institutional Review Boards. 
4.3.2 Assessment of Subclinical Cardiovascular Disease (SCVD) 
The common carotid artery (CCA) intima-media thickness was measured using B-mode 
ultrasonography with an Acuson Cypress portable ultrasound machine (Siemens Medical 
Solutions, Malvern, PA) on all participants returning for the Tobago Family Health Study 
ancillary carotid ultrasound scan in 2007. Both the near and far walls of the distal common 
carotid artery were captured for one centimeter proximal to the carotid bulb. IMT was obtained 
using semi-automated reading software (AMS system; Dr. Thomas Gustavsson, Sweden). This 
system detects and traces lines, with reader input, between the lumen-intima and media-adventia 
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borders across the 1 cm segment. Then, the software generates one thickness measurement per 
pixel across this area, for about 140 measures in total. Mean IMT measures correspond to the 
mean IMT across all pixels of both the near and far wall of the common carotid artery on both 
the right and left arteries. All images were read centrally at the Department of Epidemiology’s 
Ultrasound Research Laboratory (University of Pittsburgh, Pittsburgh, PA). Reproducibility 
analyses were conducted on 35 Tobago Family Health Study participants. The inter-sonographer 
intraclass correlation (ICC) and Inter-reader ICC were 0.97 and 0.99 for mean IMT respectively. 
The ankle brachial index (ABI) and brachial-ankle pulse wave velocity (baPWV) 
measures were automatically generated using a noninvasive and automated waveform analyzer 
(VP1000, Omron Co., Komaki, Japan). Following 10 minutes of rest in a supine position, 
occlusion and monitoring cuffs were placed around both arms and ankles, following standardized 
placement procedures.  The arm cuffs were placed on bare arms or over light clothing, and the 
ankle cuffs were placed on bare ankles. ECG electrodes were placed on both wrists and a 
phonocardiogram (PCG), which is a microphone for detecting heart sounds, was placed on the 
left edge of sternum. The cuffs were connected to a plethysmographic sensor that determined 
volume pulse waveforms and to an oscillometric pressure sensor that measured blood 
pressure. Volume waveforms for the arm (brachial artery) and ankle (tibial artery) were stored 
for a sampling time of 10 seconds with automatic gain analysis and quality adjustment. ABI was 
calculated by the ratio of the ankle systolic BP divided by the arm systolic BP, and the lower 
value of the ankle systolic BP was used for the calculation. An average of ABI, from the right 
and left sides, was used in our analyses. 
 The baPWV was calculated as (distance between arterial sites) divided by (time between 
the foot of the respective waveforms). The distance measure was calculated using height-based 
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formulas rather than the actual “above the body” distances and also corrects for the opposite 
direction of blood flood by subtracting the heart-to-brachial distance from the heart-to-tibia 
distance, as seen in the following equation (198): path length from the heart to the brachium (Lb) 
=0.2195 x height of the patient (cm) - 2.0734; path length from the heart to ankle (La) = 0.8129 x 
height of the patient (cm) + 12.328. The baPWV was calculated by time-phase analysis, for the 
right and left sides, using waveforms of the respective brachial and ankle (tibial) arterial sites, 
from the following equation: (La -Lb)/time difference between the brachial and ankle waveform.  
An average of baPWV, from the right and left sides, was used in our analyses. 
4.3.3 Laboratory Measurements 
Blood samples were obtained by venipuncture in the morning after a 12-hour fast. Whole 
blood sat at room temperature for a minimum of 20 min to clot before centrifugation. A spot 
urine sample was also collected. Aliquots of serum and urine were frozen at -20°C locally and 
shipped on dry ice by express courier within a month, and later stored in -80 °C freezers at the 
University of Pittsburgh. 
Serum cystatin C was measured at the University of Vermont from frozen samples 
collected at the baseline study visit (2004), using a protocol similar to the Cardiovascular Health 
Study (CHS) (199). A BNII nephelometer (Dade Behring, Inc, Deerfield, Ill) was used with a 
particle-enhanced immunonephelometric assay (N Latex Cystatin C, Dade Behring, Inc). The 
assay range was from 14.6 to 549.0 nmol/L (0.195 to 7.330 mg/L); the reference range for 
young, healthy persons was reported to be 40 to 71nmol/L (0.53 to 0.95 mg/L). The intra-assay 
coefficient of variation ranged from 2.0% to 2.8%, and the interassay coefficient of variation 
ranged from 2.3% to 3.1%.  
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Serum creatinine was quantitatively determined at the University of Vermont using the 
VITROS CREA Slide method. The sample was diluted with VITROS 7% BSA. Standards, 
serum controls and duplicate samples were run with each assay, which were traceable to a Gas 
Chromatography Isotope Dilution Mass Spectrometry (GC/IDMS) method and National Institute 
of Standards and Technology (NIST) SRM®914 creatinine standard reference material. 
Creatinine values traceable to this standard and the results are referred to as standardized 
creatinine values.  Urine samples were diluted with 1:1 reagent-grade water, and urinary 
creatinine was analyzed as above. The coefficient of variation between runs is 6.0%.  
Albumin in urine was measured at the University of Vermont using a turbidimetric 
procedure on the Olympus AU400 using reagents provided by Olympus America, Inc. (Center 
Valley, PA). The intra- and inter-assay coefficients of variation were below 2.5% and 5.1%, 
respectively. Metabolic traits, including triglyceride, total serum cholesterol level, low density 
cholesterol (LDL- calculated), high density cholesterol (HDL), fasting insulin and fasting 
glucose, were measured in Heinz Laboratory in the University of Pittsburgh using standard 
protocols.  
4.3.4 Disease Definitions  
Hypertension was defined as diastolic blood pressure ≥ 90 mmHg, systolic blood 
pressure ≥140 mmHg, or currently taking blood pressure medication(134). Diabetes was defined 
as fasting glucose level ≥126 mg/dl or currently taking diabetes medication(135). Obesity was 
defined as BMI ≥ 30 kg/m2. The spot albumin-to-creatinine ratio (ACR) was calculated and 
reported in milligrams per gram. According to the American Diabetes Association (ADA) (136) 
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and the National Kidney Foundation(137) criteria, albuminuria was defined as ACR > 30 mg/g; 
microalbuminuria: 30-299 mg/g and macroalbuminuria: ≥300 mg/g. 
4.3.5 Statistical Methods  
Estimated GFR was calculated using the four-variable MDRD equation for standardized 
serum creatinine. The simplified Modification of Diet in Renal Disease Study (MDRD) equation 
was used to estimate glomerular filtration rate based on serum creatinine: GFR [mL · min-1 · 
(1.73 m2) -1] = 175 × (serum creatinine [mg/dL] -1.154× age [years] -0.203[× 0.742, if female] [× 
1.212, if African American] (81). Age was included in years and serum creatinine in mg/dl.  
Before analyses, all distributions were assessed. The natural log transformation was 
applied to achieve normality for subclinical cardiovascular measures (ABI, baPWV and carotid 
IMT), renal function measures (serum cystatin C, serum creatinine, microalbuminuria and 
eGFR), cholesterol, triglyceride, insulin and glucose. Outliers (± 4 S.D) were removed to achieve 
the normal distribution. The characteristics of individuals were compared using the χ2 test 
(categorical variable) and ANOVA (continuous variables).  
Multiple linear regression models were performed to evaluate potential influencing 
factors for the association of renal measures and subclinical cardiovascular disease, without 
taking into account of participant relatedness, at 0.10 significance level using SAS 9.2. The null 
model was built with age and gender. Subsequently, traditional risk factors of cardiovascular 
disease were added to the null model, including BMI, smoking status, diabetes mellitus, blood 
pressure stages, LDL-cholesterol, HDL-cholesterol and triglycerides. Then, each renal biomarker 
(serum cystatin C, creainine, microalbuminuria and eGFR) was added into individual models to 
evaluate the relationship of each to subclinical cardiovascular disease. The significance level was 
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set at 0.05. The associations of these traits with renal measures were subsequently evaluated 
using a variance component approach as implemented in SOLAR, incorporating the effects of 
the relatedness of family members(200). Briefly, the variance components approach involves 
partitioning the variance of a quantitative trait into a component attributable to individual-
specific covariates, an additive genetic (polygenic) component and a residual non-measured 
environmental component. The significance of particular independent variables (such as diabetes 
status) were assessed by the likelihood ratio test, which compares the likelihood of a full model 
(e.g. age, BMI and diabetes status) to that of a nested model (e.g. age, and BMI only, with the 
diabetes status effect constrained to be zero). The interactions were tested between renal 
biomarkers and gender, BMI and gender.  The significance level was set at 0.05.  
4.4 RESULTS 
Among the 402 participants in the Tobago Health Study with renal function measures, the 
mean ± SD cystatin C was 0.62 ±0.19 mg/L, serum creatinine was 0.93 ± 0.23 mg/dL, and micro 
albumin was 2.6 ±9.3 mg/dL. There was no difference in the mean serum concentration of 
Cystatin C between men and women (p=0.24). Table 4.1 shows the characteristics by tertiles of 
cystatin C. Higher concentrations of cystatin C were associated with older age, higher body mass 
index, triglycerides, fasting insulin, serum creatinine and lower estimated GFR. The prevalence 
of hypertension increased across ascending tertiles of cystatin C. The heritability of serum 
cystatin C was 32% ± 0.1 (P<0.0001) after adjusting for age, gender, hypertension, triglyceride 
and insulin level. The heritability of other renal function measurements in this population has 
been reported previously (201). 
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Figure 4.1-4.3 displays the age adjusted means of subclinical cardiovascular disease 
measures. The mean ± SD baPWV was 1422.3 ± 374.0 cm/s, somewhat higher in men than in 
women (1438.4 ± 321.1 vs. 1421.3 ± 403.8, P=0.34); mean ± SD ABI was 1.05 ± 0.10, 
significantly higher in men than women (1.06±0.09 vs. 1.04±0.10, P=0.008); mean ± SD 
common carotid IMT was 0.69 ± 0.15, higher (but not significantly) in men than women 
(0.71±0.16 vs. 0.68±0.14, P=0.09). Subclinical CVD measures increased across age group in 
both men and women.  After the age of 70, the levels of ABI decreased to 1.01 ± 0.12.  Among 
older men and women, 16% (n/N) and 14% (n/N), respectively, exhibited low ABI (ABI < 0.9) 
in Tobago families. Older women also had lower carotid IMT, but the sample size was relatively 
small. 
Multiple regression analysis of the association between renal measures and ABI was 
performed and the results shown in table 4.2. The model with only age and gender explained 
14% of the total variance in ABI. By adding traditional cardiovascular disease risk factors, 
including BMI, diabetes, hypertension, LDL cholesterol, HDL cholesterol, triglyceride and 
smoking, the model explained an additional 8% of the total variance in ABI, even though none of 
the traditional risk factors was individually significant. Subsequently, serum cystatin C, 
creatinine, microalbuminuria and eGFR were added into separate models along with the 
traditional risk factors. We found that only cystatin C was significantly related to ABI (P=0.02) 
and explained an additional one percent of variance in the total variance in ABI. None of the 
other renal measures was significantly associated with ABI adjusting for all the traditional 
cardiovascular disease risk factors.  
Incorporating the effects of relatedness of family members, the association of renal 
measures with baPWV and carotid IMT was evaluated using the variance component approach 
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in SOLAR. As a basic model with only age and gender, 54% of total variance in baPWV was 
explained (Table 4.3). Adding renal measures into the individual models, Cystatin C was the 
most significant factor related to baPWV with P value = 0.0005, explaining eight more percent 
of total variance of baPWV. Serum creatinine was also significantly (P=0.04) related to baPWV 
but explained less variance (5% of total variance in baPWV). Furthermore, Table 4.4 shows the 
fully adjusted model, with hypertension, diabetes and BMI in the model additional to age and 
gender, only cystatin C was significantly related to baPWV (P=0.04). The proportion of variance 
due to covariates was 62%. Adding cystatin C into the model explained an additional 1% of 
variance. None of the other renal function measurements was significant. We did not find any 
significant results for the association between renal measures and carotid IMT (data not shown).  
4.5 DISCUSSION 
Participants in our study came from the island of Tobago, located in the Southern 
Caribbean Sea. Compared to African Americans, the Tobago population is a more homogeneous 
population of West African descent with only about 6% admixture with other ethnic groups 
(109). We found a significant heritability of cystatin C among these multigenerational Afro-
Caribbean families. The heritability of serum cystatin C was 32% ± 0.1 (P<0.0001), after 
adjusting for age, gender, hypertension, triglyceride and insulin level, which is similar to the 
reports of Framingham Offspring Study (h2=0.35, p<0.0001)(101). Further, we detected a 
significant association between peripheral arterial disease and arterial stiffness with cystatin C, 
but not with the other renal function measurements among these Afro-Caribbean families.  
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Cystatin C is a small protein that is produced throughout the body by nucleated cells and 
freely filtered by the glomeruli. When it functions normally, the kidney reabsorbs cystatin C and 
degraded by the proximal tubular epithelial cells, maintaining normal levels of serum cystatin C 
(202). But, when kidney function deteriorates, serum cystatin C is elevated due to the  
reabsorption dysfunction. Such increase occurs as the GFR falls and is often detectable before a 
measurable decrease in the GFR (203). Numerous studies found that cystatin C levels were more 
accurate for predicting GFR in various clinical presentations, especially among mild to moderate 
kidney disease patients (with a relatively higher eGFR)(85). Serum cystatin C concentration is 
not significantly affected by muscle mass, gender, age, or race (78, 79). It has been demonstrated 
that there is no correlation between cystatin C and lean tissue mass in the children(204) and 
healthy adults(143), but a modest correlation in the older subjects(205). In contrast, serum 
creatinine is a by-product of muscle cells, and is affected by many other factors than kidney 
disease such as lean muscle mass. Furthermore, using serum creatinine as a measurement to 
estimate GFR has another drawback, called ‘creatinine-blind range’. As serum creatinine 
increases in mild kidney impairment, creatinine clearance is little affected until the tubular 
secretion mechanism is saturated. Thus, the utility of serum creatinine in detection of slight to 
moderate renal dysfunction is limited (77). While there are growing data and literature providing 
support that serum cystatin C correlates with kidney disease better than serum creatinine, there is 
still a degree of uncertainty about when and how it should be used (85) (82).   
Besides the problems attributable to creatinine metabolism, creatinine measurement is 
technically problematic. Several different methods have been applied with the Jaffé method 
being the most commonly used. This assay is hampered by interferences up to 20% non-
creatinine chromogenes including acetic acid, acetone, pyruvate, glucose and ascorbic acid(196). 
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With the development of enzymatic assays, the problem of interference has been reduced but not 
eliminated (206). Low intra-assay specificity makes comparison of creatinine measurements 
across different laboratories difficult. Even the inter-assay coefficient of variation in serum 
creatinine is relatively high, 6.0%, compared to only 2.3% in serum cystatin C. Thus, cystatin C 
is a better marker, though this does not necessarily mean that it is biologically more relevant than 
serum creatinine.  
Patients with decreased renal function are highly predisposed to atherosclerotic artery 
disease. Previous study reported a remarkably high prevalence of PAD in nondialyzed  patients 
with CKD in NHANES III 1999-2000(207). Ankle brachial index is a simple, non-invasive, and 
reliable measurement to assess PAD. The presence of ABI lower than 0.9 has been found to be 
associated with an increased odds of having an estimated GFR<90 (OR: 1.54; 95% C.I.: 1.17-
2.04); such relationship appeared to be stronger among African Americans than whites (OR=1.88 
vs. 1.36) (195). Another study reported that cystatin C was  a marker of peripheral 
artherosclerotic disease, apart from its relation to kidney function(194). Similarly, we found that 
only cystatin C was highly associated with ABI in this African Caribbean population. The 
relationship between renal insufficiency and PAD is possibly due to the pathogenic mechanisms 
associated with reduced glomerular filtration rate, such as alternative metabolism of calcium, 
phosphate, and parathyroid hormone, hyper-homocysteinemia, inflammatory alterations, or 
coagulation pathway(208). 
We also found that arterial stiffness, measured by PWV, was inversely related to renal 
function independent of other risk factors(203). Elevated PWV is a marker of arterial stiffness 
and predicts cardiovascular events independent of age, gender and other traditional 
cardiovascular risk factors (209). Our finding indicated that the association between cystatin C 
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and baPWV was significant after adjusting for age, gender, hypertension, diabetes and BMI. In 
contrast, serum creatinine lost its significance in the fully adjusted model. These findings are 
consistent with previous reports. Cystatin C has been found to be associated with arterial 
stiffness in older adults(210), independent of serum creatinine and eGFR based on 
creatinine(96). However, the mechanisms underlying the relationship between the renal function 
and arterial stiffness are not fully understood. It is believed that renal failure is associated with 
structural or functional alterations exclusively located in small resistance arteries (211).  Not 
only was the stiffness of small arteries, but the stiffness occurring in large arteries was 
independently associated with reduced renal function. The increased arterial stiffness leads to 
increased pulse pressure (systolic BP – diastolic BP), which leads to deterioration in kidney 
function, eventually resulting in decreased GFR. In addition, kidney damage may cause an 
increase in other risk factors for arterial stiffness such as hypertension, anemia or vascular 
calcification(212). Such vicious cycles promote each other. However, the cross sectional nature 
of our study does not allow us to distinguish the direction of this association.  
The carotid IMT exam uses state-of-the-art ultrasound technology to measure the 
thickness of the first two layers of the carotid arteries located in the neck, where the plaque first 
develops. Abnormal, premature thickening of the arterial walls is an early sign of vascular 
disease. It has been found to be related to cardiovascular risk factors such as triglyceride, LDL, 
HDL and total cholesterol (213), and increased the risk of stroke and myocardial infarction(188, 
214, 215). A previous study also reported that patients with chronic renal failure exhibited 
significantly increased carotid IMT after adjusting for traditional risk factors(216). However, 
there was no significant association of any renal function measures with carotid IMT in our study 
samples. The Multi-Ethnic Study of Atherosclerosis (MESA) Study recently published their null 
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findings of cystatin C and IMT among 6,557 ethnically diverse persons free of clinical 
cardiovascular disease, aged 45 to 84 years ambulatory adults, suggesting that the cystatin C 
level is not significantly related to carotid IMT (217). Thus, the association between cystatin C 
and cardiovascular risk is not likely to be explained through accelerated arterial atherosclerosis. 
In contrast to the significant association between IMT and renal dysfunction among end stage 
renal disease patients who have advanced CKD, early kidney disease does not appear to be 
associated with increased levels of atherosclerosis. Furthermore, previous studies found that 
microalbuminuria but not cystatin C was related to carotid IMT beyond traditional risk factors 
among middle aged adults (218). However, this association is less consistent, especially among 
low-risk populations (219).  
Gender difference in the association between BMI, body composition and CKD, 
attributable to sex hormones has been reported before, though this association is not yet clear 
(220). Deterioration of renal function is more rapid in males than in females(221). Furthermore, 
it has been reported that high BMI is positively associated with CKD in males but not in females 
from a Singapore cohort (222). Tobago women are extremely obese in our study; the mean waist 
circumference was 89.6 ± 17.2 cm. However, a test of interaction term between BMI and gender 
was not statistically significant related to PWV measurement. Thus, the combined model was 
built up for analyzing the association between PWV and renal biomarkers.   
Our study has several limitations. Most important, as mentioned already, in any cross-
sectional study, the direction of the association cannot be ascertained. A longitudinal study 
design is needed to establish a causal relationship between these renal function biomarkers and 
subclinical CVD or CVD. Secondly, real GFR was not directly measured in this study. Although 
the MDRD equation has gained widespread acceptance and is reported by most clinical 
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laboratories, the limitation of estimation of GFR based on serum creatinine is noted and the 
major limitation is imprecision among patients with mild renal dysfunction. The MDRD 
equation had no bias for severe kidney disease patients (eGFR <60 ml/min per 1.73 m2), but 
underestimated GFR for levels of eGFR between 60 and 119 ml/min per 1.73 m2, and 
overestimated GFR for levels of eGFR >120 ml/min per 1.73 m2(223). It is also possible that 
there is residual confounding from other unmeasured factors that were not evaluated in this 
study. Third, the sample size was relatively small, which decreased the power to detect slight 
differences. The probands and family members were recruited without regard to health status, all 
participants were ambulatory, relatively young and healthy; thus the association of renal function 
biomarkers and subclinical CVD among these healthy families, so called “healthy family effect”, 
might have biased findings towards the null.  
In conclusion, our data suggest that reduced kidney function, indicated by elevated serum 
cystatin C level was significantly related to arterial stiffness and peripheral arterial disease 
among these Afro-Caribbean families. 
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Table 4.1 Charcteristics of Study Participants by Cystatin C level 
 
 Male (156) Female (246) P Value 
d  Cystatin C Tertile Cystatin C Tertile 
 1 :[0.35-0.54] 2: [0.55-0.64] 3: [0.65-1.52] 1: [0.29-0.54] 2: [0.55-0.64] 3: [0.65-1.81] 
Characteristics   
N 39 66 51 106 62 78 --- 
Age (years) 40.1±14.9 38.0±14.2 48.7±19.7 32.9±11.4 39.5±13.1 58.6±15.6 <0.0001 
Current Smoker N(%) 6 (15.4) 5 (7.7) 6 (12) 1 (1) 0 (0) 0(0) 0.35 
Hypertension N(%) 7 (18.4) 16 (24.6) 25 (50) 10 (9.4) 16 (26.2) 44 (59.5) 0.004 
Diabetes N(%) 5 (12.8) 5 (7.7) 8 (15.7) 10 (9.5) 6 (9.7) 28 (36.8) 0.13 
BMI (kg/m2) a 25.3±5.1 26.9±4.9 27.8±5.2 25.9±6.1 30.9±6.2 32.4±7.0 <0.0001 
Triglyceride (mg/dL) 78.0±23.0 93.9±53.0 105.0±60.6 67.5±24.1 89.9±37.7 106.8±55.3 0.0002 
Cholesterol (mg/dL) 184.6±36.6 188.7±48.9 191.9±37.3 173.4±37.4 190.1±36.1 217.3±48.9 0.18 
Insulin 12.9±6.7 14.2±8.6 14.3±7.3 15.2±8.6 18.4±11.5 19.2±12.8 0.04 
Glucose 86.3±21.3 83.4±24.2 87.5±19.0 84.8±35.7 83.9±15.5 100.0±33.6 0.24 
HDL (mg/dL) 39.2±11.7 42.2±11.9 40.5±11.6 39.6±11.3 37.8±12.4 40.4±14.7 0.76 
Systolic BP (mmHg) 122.5±18.1 123.2±20.2 133.6±21.3 109.0±18.2 116.8±22.3 133.6±30.1 0.30 
Diastolic BP (mmHg) 74.6±10.6 76.0±12.7 80.6±13.4 70.1±11.0 73.8±13.7 79.4±13.5 0.66 
Serum Creatinine (mg/dL) 0.96±0.1 1.01±0.1 1.13±0.2 0.77±0.1 0.8±0.1 1.1±0.6 <0.0001 
MDRD_eGFR b  109.7±26.3 103.5±18.2 90.3±25.2 117.8±24.9 108.0±24.1 78.6±28.9 <0.0001 
AC ratio (mg/g) c 2.86±4.0 5.50±26.4 11.86±31.4 9.39±32.6 14.63±38.0 45.4±108.3 0.43 
 
a BMI: body mass index 
b MDRD_eGFR: estimated GFR 
c AC ratio: Urinary albumin creatinine ratio 
c P value represents differences across cystatin C tertile, adjusted for age and gender, not taking into account sample relatedness. 
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Figure  4.1 Age Specific baPWV a by Age Group among Participants 
 
Figure 4.2 Age Specific ABI b by Age Group among Participants 
 
Figure 4.3 Age Specific IMT c by Age Group among Participants 
a : baPWV: brachial ankle pulse wave velocity, an average of left and right sides 
b : ABI: ankle brachial index, average of left and right sides 
c : carotid IMT: carotid intima-media thickness, an average of left and right sides  
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Table 4.2 Multivariate Analysis of Traditional Cardiovascular Risk Factors, Serum Cystatin C, Serum creatinine, Microalbuminuria 
and eGFR on Ankle Brachial Index (ABI) 
 
 
 
aAdjusted for traditional risk factors including age, gender, BMI, smoking status, diabetes mellitus, blood pressure stages, LDL-cholesterol, HDL-
cholesterol and triglycerides. None of the traditional risk factors is significant.  
bAdjusted R2 = 0.14, indicating the adjusted R2  for the model with only age and gender  
  
 Age- and gender-adjusted 
+Traditional risk 
factorsa 
+Traditional risk 
factors +Cystatin 
+Traditional risk 
factors +Creatinine 
+Traditional risk 
factors 
+Microalbuminuria 
+Traditional risk 
factors +eGFR 
Adjusted R2 0.14b 0.22 0.23 0.22 0.22 0.22 
 ß(SE) P ß(SE) P ß(SE) P ß(SE) P ß(SE) P ß(SE) P 
Age (years) 0.002 (0.0003) 
<.000
1 
0.002 
( 0.0004) <.0001 
0.002 
(0.0004) <0.001 
0.002 
( 0.0004) 
<.000
1 
0.002 
(0.0004) <.0001 
0.002 
(0.0004) <.0001 
Gender -0.03 (0.009) 0.002 
-0.03 
(0.01) 0.008 
-0.03 
(0.01) 0.003 
-0.035 
(0.01) 0.006 
-0.02 
(0.01) 0.01 
-0.03 
( 0.01) 0.008 
Serum cystatin C (mg/l) -0.06 (0.02) 0.006   -0.06(0.03) 0.02       
serum creatinine (mg/l) -0.05(0.03) 0.08     -0.03(0.03) 0.29     
Urinary albumin 
excretion (mg /g) 
-0.001 
(0.003) 0.76       
0.0003 
(0.003) 0.92   
eGFR  [mL * min-1 
*(1.73 m2) -1] 0.03(0.02) 0.15         
0.02 
( 0.02) 0.35 
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Table 4.3 The Association of baPWV (Age, Gender Adjusted) with Renal Measures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Null Model Serum cystatin C  Serum creatinine 
Urinary albumin 
excreation eGFR 
Proportion of variance due 
to covariates 0.54 0.62 0.59 0.59 0.59 
 ß(SE) P ß(SE) P ß(SE) P ß(SE) P ß(SE) P 
Age (years) 0.01 <0.0001 0.01 <0.0001 0.01 <0.0001 0.01 <0.0001 0.01 <0.001 
Gender -0.03 0.05 -0.04 0.01 -0.02 0.29 -0.05 0.004 -0.05 0.005 
Serum cystatin C (mg/l)   0.16 0.0005       
Serum creatinine (mg/l)     0.1 0.04     
Urinary albumin excretion 
(mg /g)       0.006 0.27   
eGFR  [mL * min-1 *(1.73 
m2) -1]         -0.08 0.07 
102 
 
 
Table 4.4 The Association of baPWV (Age, Gender, Diabetes and Hypertension Adjusted) and Renal Measures 
 Null Model Serum cystatin C  Serum creatinine 
Urinary albumin 
excreation eGFR 
Proportion of variance due to 
covariates 0.62 0.63 0.62 0.62 0.62 
 ß(SE) P ß(SE) P ß(SE) P ß(SE) P ß(SE) P 
Age (years) 0.009 <0.0001 0.008 <0.0001 0.009 <0.0001 0.009 <0.0001 0.009 <0.0001 
Gender -0.06 0.009 -0.06 0.01 -0.05 0.04 -0.06 0.01 -0.06 0.006 
Diabetes (yes/no) 0.07 0.02 0.02 0.02 0.08 0.02 0.07 0.03 0.08 0.02 
Hypertension (yes/no) 0.11 <0.0001 0.10 <0.0001 0.11 <0.0001 0.12 <0.0001 0.11 <0.0001 
BMI (kg/m2) 0.02 0.6 0.02 0.7 0.02 0.7 0.19 0.7 0.02 0.7 
Serum cystatin C (mg/l)   0.09 0.04       
Serum creatinine (mg/l)     0.003 0.55     
Urinary albumin excretion (mg /g)       -0.002 0.71   
eGFR  [mL * min-1 *(1.73 m2) -1]         -0.03 0.67 
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5.0 GENERAL DISCUSSION 
5.1 SUMMARY OF FINDINGS 
Chronic disease is becoming a major public health concern in developing countries as 
well as in developed countries. With advancing westernization of lifestyle, Afro-Caribbeans are 
at greater risk of developing chronic kidney disease, metabolic syndrome or cardiovascular 
disease. However, in contrast to numerous studies conducted in the western world, very limited 
resources are available among these minority groups who are at higher risk of chronic diseases. 
This dissertation built upon the data collection from seven multigenerational families who reside 
in the island of Tobago, and comprehensively studied the following disease conditions – chronic 
kidney disease, metabolic syndrome and subclinical cardiovascular disease among this sample 
population of African origin. The Afro-Caribbeans who reside on the island of Tobago provide a 
valuable opportunity to conduct studies in a population with a relatively homogeneous genetic 
background of western African origin, with approximately 6% admixture with other ethnic 
groups (109). 
In the effort to explain the genetic contribution to complex diseases such as CKD, CVD 
and metabolic syndrome related components, a large number of studies have been conducted for 
statistical associations with disease phenotypes among European origin populations, including 
candidate gene association studies, linkage analyses, and genomewide association studies. 
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However, even fundamental studies are sparse among minority populations. We are the first, to 
our knowledge, to report the heritability of renal function biomarkers and metabolic syndrome 
related components in an Afro-Caribbean population, confirming the existence of familial 
aggregation of diseases in this population.  
Rather than a defined clinical presentation, metabolic syndrome is combination of 
medical disorders which increase the risk of developing cardiovascular disease and diabetes. The 
prevalence of metabolic syndrome has been increasing dramatically over the recent decades. We 
found a significant heritability of metabolic syndrome related traits among Afro-Caribbean 
families. The estimated heritability ranged from 12% to 46% for fasting glucose to HDL 
cholesterol. Furthermore, to better understand the structures of clustering of these inter-
correlated metabolic traits, factor analysis was performed based on the assumption of the 
presence of common genetic and/or environmental factors underlying these components. We 
found that factor 1 comprised only of lipids, glucose and central obesity explained the majority 
of the variance (55.8%), and heritability was 29% (p=0.0001). Factor 2 comprised mainly of 
systolic and diastolic blood pressure was 20% heritable (p=0.002). Thus, with these significant 
genetic contributions to the metabolic traits, metabolic syndrome was heritable among these 
Afro-Caribbean family members.    
As a traditional renal function biomarker, serum creatinine was found to be 28% heritable 
in our study. However using serum creatinine as a measurement to estimate GFR has several 
drawbacks. It is a by-product of muscle cells, being affected by many other factors other than 
renal function, and more and more investigators have argued about the accuracy of using a serum 
creatinine based equation to estimate GFR. Thus, we tested a novel biomarker of renal function - 
Cystatin C, among these participants. Cystatin C is a small protein and produced throughout the 
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body by nucleated cells. Levels are not significantly affected by muscle mass, gender, age, or 
race (78, 79). We reported the heritability of cystatin C was 32%, after adjusting for age, gender, 
hypertension, triglycerides and insulin level. 
Patients with decreased renal function are highly predisposed to atherosclerotic artery 
disease. A previous study reported a remarkably high prevalence of PAD in nondialyzed  
patients with CKD in NHANES III 1999-2000(207). We further tested the association between 
renal biomarkers and subclinical cardiovascular measures including IMT, ABI and PWV. We 
found that only cystatin C was highly associated with ABI and PWV among this African 
Caribbean population, but not serum creatinine or estimated GFR. However, the mechanisms 
underlying the relationship between the renal function and subclinical cardiovascular disease are 
not fully understood. Due to the reduced glomerular filtration rate, renal insufficiency may result 
in alternative metabolism of calcium, phosphate, and parathyroid hormone, inflammatory 
alterations, or coagulation pathway, which might contribute to vascular abnormalities, eventually 
cause PAD. Furthermore, kidney disease may interact with not only small but also large arteries, 
increasing the risk for hypertension, anemia or vascular calcification, which eventually 
contributes to arterial stiffness.  
In conclusion, our data suggest that both reduced kidney function and metabolic 
syndrome related components are significantly heritable among Afro-Caribbean families. The 
reduced renal function indicated by elevated serum cystatin C level was associated with 
subclinical cardiovascular disease, eventually may explain a proportion of the observed 
excessive cardiovascular risk among this population. 
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5.2 STRENGTHS AND LIMITATIONS 
The study, the first to be conducted in this Afro-Caribbean population, provides 
heritability estimation of complex chronic diseases. We recruited participants from seven 
multigenerational families, with extended family members, which provide better power to detect 
genetic signals than parent-offspring or sib-pair data. Such family structure will give more 
accuracy in heritability estimation. The relationship among individuals has been validated by 
genotyping data, so we minimized the possibility of inaccurate reports of biological kinship. 
However we do have several limitations to address which might influence the findings: 1) the 
sample size was relatively small; 2) even though we recruited people without regard to their 
health status, these families were selected for large size, and participants were required to be 
ambulatory; thus a ‘healthy family effect’ cannot be excluded; 3) cross-sectional study design 
limits the ability to test the direction of the association.  
5.3 FUTURE DIRECTIONS 
Our significant heritability estimates of renal dysfunction and metabolic syndrome in 
families of African ancestry confirm a familial aggregation of these complex diseases and justify 
further analyses aimed at understanding the genetic determinants of renal function in this high 
risk ethnic group. Future studies are needed to identify underlying susceptibility genes or regions 
on the chromosome which contribute to the disease susceptibilities. Obtaining genotype data on 
markers across genome, by performing genomewide association study or genomewide linkage 
analyses, would enable the identification of genes contributing to the disease susceptibility. 
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Our findings could be extended to some additional measurements or calculation of GFR 
to better understand renal function among this population. The gold standard measurement of 
renal function is by measuring the clearance of injected inulin. Renal function is routinely 
estimated based on serum creatinine using the MDRD equation. The CKD-EPI (Chronic Kidney 
Disease Epidemiology Collaboration) has recently published as a new estimating equation for 
GFR (REF). The comparison of the accuracy between different equations could provide insight 
and suggestions for routine use in epidemiological studies and in the clinical setting.    
The cross-sectional nature of this project limits our ability to test the direction of the 
association. Longitudinal data collection will bring the important insights of the disease 
causality. For example, the association between CKD and CVD remains as a question of 
‘chicken’ or ‘egg’, which comes from first?   
5.4 PUBLIC HEALTH SIGNIFICANCE 
Through this project, we estimated the genetic impact of the following important chronic 
diseases conditions among African Caribbean population.  
Chronic kidney disease (CKD) is a major, growing public health problem, and is 
particularly prevalent among populations of African descent. Higher prevalence of diabetes 
mellitus and hypertension account for part of this excess risk for kidney disease, and all three 
conditions increase risk of cardiovascular disease. In Trinidad and Tobago, 20 % renal failure 
occurs among the working –age population, which brings a huge economic burden.  
Chronic cardiovascular disease (CVD) is the leading cause of death worldwide.  Tobago 
population is at high risk of hypertension, diabetes, cardiovascular disease and impaired kidney 
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function. WHO statistics for Trinidad & Tobago document the highest rate of death due to CVD 
of any country outside the former Soviet Union. Morbidity of chronic renal disease and its 
reporting are complicated by the fact that the incidence of cardiovascular diseases, including 
morbid events, increases with the severity of renal disease. Indeed, the main cause of death in 
chronic renal disease is cardiovascular disease and not renal disease(224).  This leads to the 
likely under-reporting of renal disease in the clinical setting and on death certificates. 
Although inheritance is a recognized determinant of cardiovascular disease, metabolic 
syndrome, and kidney dysfunction, little is known about the genetic contributions to renal 
dysfunction in families of African descent. The results of this project provide the first 
comprehensive heritability estimation of important complex diseases among this Afro-Caribbean 
population. Not only did our findings confirm the familial aggregation of diseases, but also 
benefit future studies among this minority group of population for these important phenotypes. It 
is believed that this project contributes to a better understanding of genetic and environmental 
impact of disease susceptibility, leading to the possibility of better disease control and prevention 
in the Afro-Caribbean community.   
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